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ABSTRACT 
Background: Cognitive behaviour therapy (CBT) is an effective, well-established, but 
not widely available treatment for social anxiety disorder (SAD). Internet-based 
cognitive behavior therapy (ICBT) has the potential to increase availability and 
facilitate dissemination of therapeutic services for SAD. However, research is needed 
to establish efficacy, effectiveness, long-term effects, cost-effectiveness and potential 
determinants of treatment outcome. 
 
Aims: The present thesis aimed at investigating the following: a) The efficacy of ICBT 
for SAD in a university setting (Study I), b) the effectiveness of ICBT for SAD in a 
psychiatric setting (Study II), c) The effects of ICBT for SAD over 5 years (Study III), 
d) The cost-effectiveness of ICBT for SAD compared to conventional CBT (Study IV), 
and e) Clinical and genetic determinants of ICBT for SAD in relation to conventional 
CBT (Study V). 
 
Methods: Two large scale randomised controlled trials (RCTs) were conducted. In the 
first RCT (Study I), ICBT (n=40) was compared to CBT bibliotherapy (n=40) and a 
waiting list control (n=40). The second RCT (Study II) was a non-inferiority trial 
comparing ICBT (n=64) to cognitive behavioural group therapy (CBGT; n=62) in a 
clinical setting. In Study III, a 5-year follow-up assessment was conducted of 
participants of Study I. In Study IV, a prospective cost-effectiveness and cost-utility 
analysis of ICBT compared to CBGT was conducted using a societal perspective. 
Based on clinical and genetic data collected in Study II, predictors and moderators of 
treatment outcome of ICBT in relation to CBGT were investigated in Study V. 
 
Results: Study I: ICBT for SAD yielded large effect sizes on measures of social 
anxiety and demonstrated superiority to waiting list controls and a trend towards 
superiority of CBT bibliotherapy. Study II: ICBT for SAD was well within the non-
inferiority margin compared to CBGT on the primary outcome measure. Study III: 
Participants receiving ICBT for SAD made further improvements from post-assessment 
to 1-year follow-up. These improvements were maintained at 5-year follow-up. Study 
IV: The incremental cost-effectiveness ratio was -7042 USD, suggesting that ICBT 
compared to CBGT leads to incremental gains to a lower cost. Study V: Demographic, 
clinical and therapy related factors predicted outcome of CBT. A few clinical factors 
moderated treatment outcome of ICBT in relation to CBGT. None of the investigated 
candidate genes had an impact on treatment outcome. 
 
Conclusions: ICBT for SAD is efficacious, effective in a clinical setting, long-term 
effective and, compared to conventional CBT, cost-effective regardless of willingness 
to pay. In addition, treatment outcome can be predicted. ICBT for SAD is ready for 
implementation and dissemination.  
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ZUSAMMENFASSUNG 
Hintergrund: Kognitive Verhaltensterapie (KVT) hat sich in der Behandlung der 
Sozialen Angststörung (SA) als effektiv erwiesen. Der Zugang zu traditioneller KVT 
bleibt aber begrenzt. Internetbasierte KVT (IKVT) hat den Vorteil, dass sie vielen 
Patienten Zugang zu KVT verschaffen kann. Allerdings ist mehr Forschung notwendig, 
um die kurz- und langfristige Wirksamkeit, sowie die Kosteneffektivität  dieser 
vielsprechenden Therapieform zu evaluieren. Im Weiteren sollten Prädiktoren und 
Moderatoren des Behandlungserfolgs identifiziert werden.  
 
Ziele: In der vorliegenden Doktorarbeit wurde Folgendes untersucht: a) Die Wirkung 
einer IKVT zur Behandlung der SA in einem Universitätskontext (Studie I), b) Die 
Wirkung einer IKVT zur Behandlung der SA in einem klinischen Kontext (Studie II), 
c) Die langfristige Wirksamkeit der IKVT (Studie III), d) Die Kosteneffektivität der 
IKVT  im Vergleich zu konventioneller KVT (Studie IV), and e) Prädiktoren und 
Moderatoren des Behandlungserfolgs bei IKVT im Vergleich zu KVT (Studie V). 
 
Methoden: Die Basis für die vorliegende Doktorarbeit bilden zwei große randomisiert- 
kontrollierte Studien (RCTs). In der ersten Studie wurde eine IKVT (n=40) mit einer 
Bibliotherapiebedingung (n=40) und einer Wartelistekontrollgruppe (n=40) verglichen. 
Die zweite Studie wurde als eine non-inferiority-Studie  konzipiert, in welcher IKVT 
(n=64) mit Kognitiv-Behavioraler Gruppentherapie (KBGT; n=62)  verglichen wurde. 
Bei der dritten Studie ging es um eine Langzeit-Katamnese, in welcher Patienten der 
ersten Studie ein Jahr und fünf Jahre nach Therapieabschluss untersucht wurden. In der 
vierten Studie wurde die Kosteneffektivität der IKVT im Vergleich zur KBGT 
untersucht, wobei volkswirktschaftliche Kosten mitberücksichtigt wurden. In der 
fünften Studie wurden  schließlich Prädiktoren und Moderatoren des 
Behandlungserfolgs bei IKVT im Vergleich zu KBGT exploriert.   
 
Ergebnisse: Studie I: Die IKVT-Bedingung war der Kontrollbedingung statistisch 
signifikant überlegen, wobei die Effektstärken auf primären Massen der sozialen Angst 
groß waren. Im Vergleich zur Bibliotherapiebedingung zeigte sich ein Trend zu einer 
Überlegenheit der IKVT. Studie II: Im Vergleich zu KBGT bewegten sich die Effekte 
der IKVT auf primären Ergebnismassen im Bereich der definierten Nicht-
Unterlegenheitsgrenzen.  Studie III: Bei Probanden die mit IKVT behandelt wurden, 
fanden sich weitere Verbesserungen vom Post- zum 5-Jahres-Katamnese 
Messzeitpunkt. Studie IV: Im Vergleich zur KBGT erwies sich die IKVT als 
kosteneffektiver. Die inkrementelle Kosteneffektivitätsrelation betrug -7042 USD. 
Studie V: Klinische Faktoren sagten den Therapieerfolg in der KVT vorher. Das 
Ergebnis wurde nicht durch die untersuchten Kandidatengene beeinflusst.  
 
Schlussfolgerungen: Die IKVT zur Behandlung der SA hat sich sowohl in einem 
experimentellen als auch in einem klinischen Setting als kurz- und langfristig wirksam 
erwiesen. Unabhängig von der Zahlungsbereitschaft von Kostenträgern, stellt IKVT bei 
SA im Vergeich zu konventioneller KVT eine kosteneffektive Behandlung dar. Die 
Implementierung von IKVT zur Behandlung von SA kann empfohlen werden. 
  
Schlüsselwörter: Kognitive Verhaltensterapie, Soziale Angststörung, Internet 
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1.1 INTRODUCTION 
In his seminal opus on human character and causes of psychic distress from 1621, “The 
Anatomy of Melancholy”, Robert Burton cites the following observation made by 
Aristotle regarding a patient: 
 
 “He dare not come into company for he should be misused, 
disgraced, overshoot himself in gestures and speeches or be sick; 
he thinks every man observeth him” [1].  
 
Thus, it seems like the basic psychological features of what today is referred to as 
social anxiety disorder (SAD) are no new appearances. Of course, the term SAD was 
unfamiliar to Robert Burton. However, his clinical vignette indicates that what we 
denote as SAD using contemporary psychiatric terminology has been a psychological 
phenomenon for centuries.  
 
With the advent of the DSM-III in 1980 [2] SAD, or social phobia, was established as 
a psychiatric diagnosis adopting the main criteria of persistent fear of social situations 
based on an exaggerated belief of  embarrassment. Although showing a close 
resemblance to normal shyness, indeed it might be that they are different points on the 
same continuous scale, SAD is by definition distinctly different in terms of its 
consequences.  
 
The person affected with SAD has an increased risk of quitting school prematurely [3], 
being unemployed [4], and developing substance abuse disorders and other psychiatric 
disorders [5]. Considering that SAD typically has an early onset [6] and often follows a 
chronic course [7], the suffering accompanying SAD is far from normal. From a 
societal perspective, the aversive consequences of SAD are costly, which to a large 
extent is due to the fact that SAD is one of the most common psychiatric disorders 
affecting up to 15% of the population [8]. 
 
In the last 25 years, cognitive behaviour therapy (CBT) has been shown to be effective 
for SAD and is today the most well-established psychological treatment [9, 10]. 
However, for several reasons the availability of CBT is limited [11] giving a need for 
treatments that are as effective as conventional CBT but requiring less resources. 
Internet-based CBT (ICBT), essentially Internet-delivered bibliotherapy with online 
therapist contact, seems to meet these criteria [12].  
 
By the time of the drafting of the research plan underlying this thesis, only two 
randomised trials had been published on ICBT for SAD, both conducted by members 
of my research group [13, 14]. Although the results were promising several aspects 
remained to be investigated and I viewed the following as pivotal: a) Can ICBT be 
efficacious when relying solely on therapist contact via the Internet, b) How effective 
is ICBT compared to conventional CBT when conducted in a clinical setting, c) Are 
the effects of ICBT long term enduring, d) Is ICBT cost-effective compared to 
conventional CBT, and d) Is it possible to identify variables that predict and moderate 
outcome of ICBT compared to conventional CBT?  
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The empirical studies, I through V, presented in this thesis are an attempt to answer 
these questions. In the process of conducting these studies ICBT for SAD has gone 
from being an interesting experimental treatment with strong potential, to a validated 
treatment ready for implementation in regular psychiatric care. My hope is that the 
scientific work presented here has and will contribute to reduced suffering and 
increased quality of life for the many affected by SAD. 
 
 
 
 
 
 
 
 
 
Stockholm, March 2011  
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1.2 SOCIAL ANXIETY DISORDER (SAD) 
1.2.1 Diagnostic features of SAD 
As diagnostic characteristics of psychiatric disorders are established through consensus 
agreements in a constantly ongoing process, what constitutes SAD is by nature unstable 
over time [15]. There are two internationally adopted systems for classification of 
psychiatric disorders: the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) system provided by the American Psychiatric Association [APA; 16], and the 
International Classification of Diseases (ICD) developed by the World Health 
Organization [WHO; 17]. The DSM and ICD systems are intended to be non-
theoretical and descriptive rather than nosological and based on aetiology [18]. This is 
essential as it means that, by definition, the SAD diagnosis is nothing more than its 
symptoms. Thus, once a person previously diagnosed with SAD no longer meets the 
criteria, he or she no longer has the disorder.  
 
As displayed in Table 1, the latest editions of the two systems, DSM-IV [15] and ICD-
10 [19] provide similar but not identical definitions of SAD. In clinical research on 
psychiatric disorders, the DSM-IV is more widely used than the ICD-10 [20, 21], 
presumably due to the fact that the DSM-system is devoted entirely to the psychiatric 
field [15]. 
 
SAD first appeared in 1980 in the third edition of DSM (DSM-III). The description was  
conceptually similar to specific phobias thus assuming a fear limited to few situations 
yielding minor functional impairment [22]. The diagnostic criteria were revised in the 
DSM-III-R [23] and the DSM-IV [15] and the name social anxiety disorder was 
suggested as way of recognising the aversive consequences of SAD [24]. According to 
the DSM-IV, the main diagnostic feature of SAD is “a marked and persistent fear of 
one or more social or performance situations in which the person is exposed to 
unfamiliar people or to possible scrutiny by others. The individual fears that he or she 
will act in a way (or show anxiety symptoms) that will be humiliating or 
embarrassing”. More specifically, this could be a fear of sweating or blushing when 
talking at a job meeting, or a fear of being appraised as inadequate by others when 
conversing at a party.  
 
A key criterion of the diagnosis is E (DSM-IV), which stipulates that the fear or the 
accompanying avoidance behaviours yield significant functional impairment. Turk and 
co-workers provide  a good clinical description of this in the report of a SAD patient 
working as a janitor despite having a college degree and who refuses to accept 
promotions and pay increase due to a fear of supervising others [25]. This impairment 
criterion is important as it separates SAD from the occasional social anxiety, which 
nearly everyone experiences, that can be coped with without profound negative impact. 
 
As can be read from Table 1, the main difference between the DSM-IV and ICD-10 
systems is that the latter is somewhat more restrictive. This is shown in that the ICD-10 
criteria require a certain number of anxiety symptoms to be reached. In addition, these 
symptoms must have specific physical aspects, such as blushing or fear of vomiting. 
This means that individuals whose anxiety is limited to fears of sweating or trembling 
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in social situation do not fulfil diagnostic criteria according to ICD-10. These 
differences are likely to explain some of the variance in prevalence rates between 
studies as described below in the Clinical characteristics section [3]. 
 
Table 1. Criteria of social anxiety disorder according to DSM-IV and ICD-10  
 
Criterion 
 
DSM-IV, Description of criterion 
 
ICD-10, Description of criterion 
 
A 
 
A marked and persistent fear of one or more social or 
performance situations in which the person is exposed 
to unfamiliar people or to possible scrutiny by others. 
The individual fears that he or she will act in a way (or 
show anxiety symptoms) that will be humiliating or 
embarrassing. Note: In children, there must be 
evidence of the capacity for age-appropriate social 
relationships with familiar people and the anxiety must 
occur in peer settings, not just in interactions with 
adults.  
 
Either (1) or (2): (1) marked fear of being the focus 
of attention, or fear of behaving in a way that will be 
embarrassing or humiliating; (2) marked avoidance 
of being the focus of attention or situations in which 
there is fear of behaving in an embarrassing or 
humiliating way. These fears are manifested in 
social situations, such as eating or speaking in 
public; encountering known individuals in public; or 
entering or enduring small group situations, such as 
parties, meetings and classrooms. 
 
B 
 
Exposure to the feared social situation almost 
invariably provokes anxiety, which may take the form 
of a situationally bound or situationally predisposed 
panic attack. Note: In children, the anxiety may be 
expressed by crying, tantrums, freezing, or shrinking 
from social situations with unfamiliar people. 
 
At least two symptoms of anxiety in the feared 
situation at some time since the onset of the 
disorder, as defined in criterion B for F40.0 
(Agoraphobia) and in addition one of the following 
symptoms: (1) Blushing, (2) Fear of vomiting, (3) 
Urgency or fear of micturition or defecation. 
 
C 
 
The person recognises that the fear is excessive or 
unreasonable. Note: In children, this feature may be 
absent.  
 
Significant emotional distress due to the symptoms 
or to the avoidance. Recognition that the 
symptoms or the avoidance are excessive or 
unreasonable. 
 
D 
 
The feared social or performance situations are 
avoided or else are endured with intense anxiety or 
distress.  
 
Symptoms are restricted to or predominate in the 
feared situation or when thinking about it. 
 
E 
 
The avoidance, anxious anticipation, or distress in the 
feared social or performance situation(s) interferes 
significantly with the person's normal routine, 
occupational (academic) functioning, or social activities 
or relationships, or there is marked distress about 
having the phobia. 
 
Most commonly used exclusion criteria: Criteria A 
and B are not due to delusions, hallucinations, or 
other symptoms of disorders such as organic 
mental disorders (F0), schizophrenia and related 
disorders (F20-F29), affective disorders (F30-F39), 
or obsessive compulsive disorder (F42), and are 
not secondary to cultural beliefs. 
 
F 
 
In individuals under age 18 years, the duration is at 
least 6 months. 
 
 
G 
 
The fear or avoidance is not due to the direct 
physiological effects of a substance (e.g., a drug of 
abuse, a medication) or a general medical condition 
and is not better accounted for by another mental 
disorder (e.g., Panic Disorder With or Without 
Agoraphobia, Separation Anxiety Disorder, Body 
Dysmorphic Disorder, a Pervasive Developmental 
Disorder, or Schizoid Personality Disorder).  
 
 
H 
 
If a general medical condition or another mental 
disorder is present, the fear in Criterion A is unrelated 
to it, e.g., the fear is not of Stuttering, trembling in 
Parkinson's disease, or exhibiting abnormal eating 
behaviour in Anorexia Nervosa or Bulimia Nervosa.  
 
 
 
Subtype 
 
Specify if Generalised subtype: the fears include most 
social situations 
 
 
 
Note: Criteria for ICD-10 refer to the research version. 
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1.2.1.1 Subtypes of SAD and avoidant personality disorder 
One of the major revisions of DSM-III-R was the added possibility of classifying 
persons with SAD according whether the disorder was generalised (GSAD) or not  
[23]. The generalised form is characterised by the presence of social anxiety in most 
social situations rather than just a few, such as a pure public speaking fear, and this 
classification dimension is retained in the DSM-IV. This change was accompanied by 
the abolition of the hierarchical relationship between SAD and avoidant personality 
disorder (APD) present in DSM-III meaning that a diagnosis of SAD could not be 
present if criteria for APD were met. There is a fairly robust empirical ground for 
distinguishing between subtypes of SAD, i.e. generalised or not. For example, persons 
with generalised SAD experience more impairment, have lower rates of spontaneous 
recovery and are more likely to have a comorbid axis-I disorder [5, 26, 27].  
 
The clinical validity of APD as a distinct category separated from SAD, on the other 
hand, has been questioned in several studies. Instead, the “continuum hypothesis” has 
been suggested, meaning that SAD and APD represent the same underlying condition, 
with APD being a more severe form of SAD [28]. There are several arguments for this. 
First, the diagnostic criteria of APD are strikingly similar to those of SAD with the 
main criteria being a persistent pattern of social inhibition, feelings of inadequacy, and 
hypersensitivity to negative evaluation [29] . Second, APD and SAD tend to coexist. In 
a review of 13 studies reporting on the comorbidity of SAD and APD, Reich found an 
average overlap of 52% [30]. Third, persons with SAD with comorbid APD respond to 
pharmacological [31, 32] and psychological treatments [33, 34], refuting the general 
criteria of personality disorders as enduring, inflexible and pervasive.  
 
Taken together, findings seem to suggest that a distinction within the social anxiety 
domain is valid, but that this is to be made between non-generalised SAD on the one 
hand and GSAD/APD on the other.  
 
1.2.2 Clinical characteristics 
1.2.2.1 Feared situations  
Several studies have shown that the most commonly feared social situation, among 
persons with SAD as well as in the general population, is public speaking [8, 35, 36]. 
Among those with SAD speaking in front of others is feared by as many as 78%-89% 
[8, 37]. Perhaps due to methodological differences, e.g. how fears are phrased and 
assessed, there seems to be no distinct order of prevalence of other social fears. In the 
national comorbidity survey replication (NCS-R), the second and third most common 
fears were speaking up in a meeting/class (85%) and meeting new people (80%) [35]. 
In a Swedish study, the second most common fear was being addressed in a group of 
people (25%) followed by maintaining a conversation with someone unfamiliar (23%) 
[8].  
 
For most persons with SAD, fearing more than one social situation is the rule. In the 
NCS-R study, less than one percent of those with life time SAD reported that they 
feared a single situation. In the same study, 71% feared at least 8 situations which was 
used as cut-off criterion for generalised SAD.    
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1.2.2.2 Course of illness 
SAD is often described as a chronic condition meaning that few of the affected 
experience spontaneous recovery [e.g. 25, 38]. There are however three central aspects 
to consider when interpreting studies estimating the course of illness of SAD: a) criteria 
for remission, b) type of sample i.e. does the cohort comprise a clinical or a community 
sample, and c) whether SAD has been assessed prospectively or retrospectively.  
 
There is a substantial body of knowledge suggesting that SAD has an early onset. In a 
large epidemiological study, Kessler and co-workers found that 75% of persons with 
SAD had an onset earlier than age 15 [6] and other studies have found a mean age of 
onset between 11 and 13 [6, 39].  
 
Most studies conducted using a retrospective design have found that SAD rarely remits. 
The duration of SAD reported is typically several decades with duration spans from 19-
40 years and remission rates between 27-50% suggesting a chronic course for a 
majority of the affected [7, 35, 40, 41]. However, when comparing these results to 
studies using a prospective design the picture is slightly different, meaning that larger 
proportions remit. In the Early Developmental Stages Study [42] assessing young 
persons, as many as 89% did not retain their SAD diagnosis at 4-year follow-up, 
although this rate dropped to 53% if stricter criteria for remission were applied. 
Compared to prospective studies on clinical samples, these rates of remission are very 
high. A prospective study examining data from the Harvard/Brown Anxiety Research 
Program showed that the natural course of SAD in a clinical sample was that 32% of 
the men and 38% of the women with SAD were in remission at 8-year follow-up.  
 
Taken together, these findings indicate that SAD might indeed be chronic, but this is 
likely to hold more for persons with SAD seeking treatment than for the general SAD 
population. A reasonable interpretation of the findings is that the course of SAD might 
be less stable in children and adolescents, but that when entering adulthood the social 
anxiety stabilise and spontaneous recovery rarely occurs [43, 44].  
 
1.2.2.3 Functional impairment and sociodemographic correlates 
”I’m not mentally able to withstand that. I have a social phobia and 
cannot stand these large crowds of people. But I will certainly write a 
speech”. – Elfride Jelinek, 2004 Nobel Prize winner in literature on being 
asked if she would travel to Stockholm to collect the prize in person [45]. 
 
There is solid evidence demonstrating that SAD is associated with functional 
impairment in several life domains [46]. Persons with SAD have an increased risk of 
unemployment or having a job below ones qualifications [4, 47, 48], have lower 
academic attainment [8, 40], are more often on disability pension [49] and are 
functionally impaired by the anxiety in their general social life as well as in close 
relationships [35]. In addition, SAD leads to reduced quality of life [4, 50], an increased 
risk of alcohol and drug abuse (see Comorbidity below) [51, 52], and poorer somatic 
health [49]. Naturally, the causal link between SAD and the impairment domains is 
difficult to claim on empirical grounds. However, when it comes to the work life 
domain, persons with SAD attribute their difficulties to social anxiety [4]. In the area of 
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substance abuse, it has been suggested that the fact that SAD precedes alcohol abuse, 
and that the effect remains after controlling for relevant potential confounders, makes 
SAD a unique risk factor [51]. In addition, Ruscio and co-workers found that, when 
controlling for comorbid psychiatric disorders, SAD remained a significant predictor of 
severe functional impairment [35]. 
 
1.2.2.4 Prevalence 
The prevalence rate of SAD has been investigated in more than 40 studies worldwide 
[36]. Table 2 displays large scale community prevalence studies using samples from the 
adult general population and DSM-III-R, DSM-IV or ICD-10 criteria. Although it 
seems clear that SAD is a highly prevalent disorder, the prevalence estimates have been 
shown to vary considerably across studies.  
 
Several aspects have to been taken into account when evaluating studies on the 
prevalence of SAD. First, the diagnostic criteria used tend to affect prevalence rates 
meaning that using DSM-III-R and DSM-IV give higher rates than when using ICD-10 
or DSM-III criteria [3, 53]. As pointed out by Furmark, the lifetime prevalence in two 
similar large scale community studies in the USA, the Epidemiologic Catchment Area 
Program [53] and the National Comorbidity Survey (NCS) [54] differed from 2.4% 
(DSM-III criteria) to 13.3% (DSM-III-R criteria).   
 
Second, as the impairment criterion of the SAD diagnosis allows for a significant 
amount of subjectivity, the demarcation condition separating subsyndromal social 
anxiety from SAD has an impact on prevalence rate. In a Canadian study, the point 
prevalence of SAD varied from 18.7% if the impairment criterion was defined as 
“moderate interference or distress” to 1.9% if the impairment was defined as “marked 
interference” [55]. Similar effects was observed in a Swedish study where the point 
prevalence ranged from 15.6% to 1.9% depending on the degree of distress used to 
define SAD cases [8].  
 
A third aspect to bear in mind when considering prevalence is the length of the 
observation period. Some studies report the lifetime prevalence, e.g. [53, 56]. This 
usually means that participants are encouraged to state whether they have fulfilled 
criteria for SAD during their lifetime. Naturally, this has the effect that prevalence rates 
increases, in one paper based on the NCS [54], the prevalence dropped from 13.3% to 
7.9% when lifetime prevalence was compared to 12-month prevalence.  
 
A very stable finding from epidemiological studies on SAD is that women have a 
higher risk of developing the disorder [36]. Considering sample size and 
methodological strengths it is likely that the best estimate is around 1.5:1 [36]. 
  
 
 
 
 
 
 
   9 
Table 2. Adult prevalence rates of SAD from community-based studies 
  
Study Prevalence 
rate 
Type of 
prevalence 
Country N Year 
Slade et al. [57]* 4.7 1-year  Australia 8848 2009 
Andrews et al. [58]* 
Lampe et al. [47] 
1.3 & 2.3
a
  1-year  Australia 10641 2001 
1.0 & 1.4a  1-month     
Offord et al. [59] 6.7 1-year  Canada 9953 1996 
Stein et al. [55] 7.1 Point Canada 526 1994 
Pellisolo et al. [60] 1.9b or 7.3c  Lifetime France 13127 2000 
0.9
b
 r 2.3 
c
  1-month    
Lepine et al. [61] 3.8a Lifetime France 1787 1995 
2.1
a
 1-year    
Faravelli et al. [37] 3.1 Lifetime Italy 2355 2000 
Furmark et al. [8] 15.6 Point Sweden 1202 1999 
Bijl et al. [62] 7.8 Lifetime The Netherlands 7076 1998 
4.8 12-month    
3.7 1-month    
Kessler et al. [6, 63] 12.1 Lifetime United States 9282 2005 
6.8 12-month    
Magee et al. [3] & 
Kessler et al. [54]  
13.3 Lifetime United States 8098 1996, 1994 
7.9 1-year    
4.5 1-month    
      
Note: *=Used ICD-10 diagnostic criteria (all other studies used DSM-III-R or DSM-IV criteria) 
a=Weighted combined estimate of males and females; b=narrow SAD definition, c=broad SAD 
definition 
 
1.2.2.5 Comorbidity  
Several epidemiological studies have shown that SAD is associated with an elevated 
risk of developing other psychiatric disorders [35, 63-65]. In fact, as more than 50% of 
individuals with SAD have been shown to have another axis-1 disorder in their life 
time, comorbidity is the rule rather than the exception [35, 65]. The most common 
comorbid disorders are anxiety disorders (e.g. panic disorder, generalised anxiety 
disorder) and mood disorders (e.g. major depression) [3, 65, 66]. However, persons 
with SAD also have an increased risk of developing substance abuse disorders and 
impulse-control disorders [5, 35, 65]. As mentioned in the Subtypes of SAD section, 
the comorbidity with avoidant personality disorder has been shown to be as high as 
89% [67] in some studies making this diagnosis the most comorbid with SAD, possibly 
reflecting that both disorders express the same underlying phenomenon.  
 
Prospective studies have shown that SAD typically precedes the comorbid psychiatric 
disorders, e.g. depression [64] and alcohol dependence [51, 68]. It has also been shown 
that having SAD typically predicts a more severe form of depression compared to 
depressed persons without SAD [64]. As stated above, these findings have lead to the 
suggestion that SAD might be a causal risk factor for developing other psychiatric 
disorders [52, 64, 68]. However, this hypothesis remains to be corroborated. 
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1.2.3 Health economic aspects of SAD 
The functional impairment associated with SAD [49], together with the 
epidemiological characteristics of the disorder such as high prevalence [36], early onset 
[6], and the chronic course [69] contribute to making SAD a costly disorder. The 
economic consequences are substantial from a societal perspective [70] as well as for 
the affected individual [71].  
 
Societal costs for SAD can be broadly classified in three different categories [70]. The 
first is direct medical costs, i.e. costs related to health care consumption (e.g. general 
practioner (GP) visits, pharmacological drugs). The second cost domain is non-direct 
medical costs, which are costs of other health-related services not directly associated 
with health care (e.g. time spent in self-help groups). Finally, a third important cost 
domain is non-medical costs, which are costs pertaining work and domestic 
productivity loss [72]. To my knowledge, only one study has been published reporting 
on the societal costs of SAD in the general population. In that study, conducted in the 
Netherlands, the total annual per capita cost for SAD was €11 952 (95% CI, 7891-
16013) which was significantly higher than the annual costs for persons without 
psychiatric disorders (€ 2957, 95% CI, 2690-3234) [70]. The costs for SAD remained 
significantly higher than for controls also after including comorbid disorders as 
covariates.  
 
In the same study, the annual costs of SAD per million inhabitants ranged from € 574 
million (crude estimate) to € 277 million (adjusted for comorbid psychiatric and 
somatic disorders) [70]. The costs of SAD were largely driven by non-medical costs 
meaning that costs were a consequence of productivity loss rather than with health care 
consumption [70]. These data indicate that SAD has a profound societal cost impact 
and that it is essential to conduct economic evaluations of interventions aimed at 
treating or preventing SAD. 
 
1.3 AETIOLOGY AND MAINTENANCE OF SAD 
As outlined by Ollendick and Hirshfeld-Becker, the developmental process of such a 
complex psychological phenomenon as SAD, is unlikely to be captured in a few cause 
and effect relationships that can be easily predicted in a mechanistic model [73]. 
Nevertheless, this section will start by describing separate factors that might contribute 
to the development of SAD. This will be followed by a presentation of cognitive 
behavioural models through which maintenance of SAD can be understood once the 
disorder is established. Finally, an attempt is made to link these interactive variables 
together. 
 
1.3.1 Heritability and genetic contribution 
Several classical twin studies have been conducted in the area of SAD [74-76]. The 
estimated genetic contribution of SAD has been shown to vary considerably between 
studies, yielding a range of explained variance of 25-50% [74, 77, 78]. One unresolved 
issue in this area is whether there is a specific genetic effect leading to SAD or if 
genetics give a predisposition to develop internalising psychiatric disorders (e.g. 
anxiety disorders and major depression) in general. Results from the Missouri Female 
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Twin Study showed that genetic factors were completely shared between SAD and 
major depressive disorder indicating a general genetic vulnerability [39]. However, one 
large study showed that a genetic factor specifically related to SAD was nearly three 
times stronger than the genetic factor common to internalising disorders, suggesting a 
more specific predisposition to SAD [75].  
 
Studies assessing the concordance of SAD within twin pairs can yield estimates of the 
general effect of genetics. However, they say nothing about which specific genes that 
might be involved. More than 25 studies have shown that allelic variation in the 
insertion/deletion serotonin transporter gene promoter (5-HTTLPR) polymorphism is 
associated with characteristics relevant to SAD [79]. The proposed mechanism is that 
carriers of the Short allele in the Long/Short polymorphism have reduced 
transcriptional efficiency and that this is associated with less extracellular synaptic 
serotonin availability yielding elevated amygdala reactivity [80, 81]. Other gene 
candidates that are less studied but theoretically interesting due to their contribution in 
amygdala responsivity are the catechol-O-methyltransferase gene (COMTval158met) 
[82] and brain derived neurotrophic factor (BDNFval66met) gene [80].  
 
Overall, it seems clear that genetic factors play a fairly important role in the aetiology 
of SAD. Just as clear is that the pathways between genotypic and phenotypic 
expression are poorly understood and that it is highly likely that the lion’s share of the 
genetic contribution is not to be find in a few polymorphism but in many genes that are 
perhaps working in complex interactive patterns.    
   
1.3.2 Behavioural inhibition 
The temperament trait most studied in relation to SAD is behavioural inhibition which 
is the disposition to be cautious, quiet, timid, and behaviourally withdrawn when 
presented to novel stimuli [83, 84]. Symptoms predictive of behavioural inhibition at 21 
months of age have been found in infants as young as four months old [85], suggesting 
an early development of the trait. Prospective studies assessing behavioural inhibition 
in early childhood (1.3-7.0 years) has demonstrated the trait leads to a 3-4 folded 
increased risk of SAD at middle childhood [86] and in adolescence [87]. Indicating a 
close link to SAD in particular, in these studies as well as in retrospective ones [88, 89], 
the effect of behavioural inhibition was specific to SAD meaning that it was not 
associated with development of any other anxiety disorders. There seems to be a 
somewhat stronger link between behavioural inhibition and generalised SAD than to 
the non-generalised subtype [66, 89], possibly suggesting that generalised SAD might 
be more contingent on early temperamental dispositions than non-generalised SAD.  
 
1.3.3 Social skills deficit 
According to the social skills deficit hypothesis, SAD can at least partially be explained 
as a result of an inadequate or inappropriate behaviour repertoire leading to negative 
social encounters [90]. The role of social skills deficit in social skills deficit in social 
anxiety has been investigated in more than 20 studies [91], however with inconsistent 
findings. Whereas research on adults has yielded mixed results with several well 
conducted studies showing no or minimal skills deficit effects [92-94], it is fairly clear 
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that children with SAD have reduced social skills compared to controls without SAD 
[91, 95, 96].  
 
Two theoretical difficulties deserve mentioning when discussing aetiological role of 
social skills deficit in SAD. First, it is of great difficulty to isolate the effect social skills 
on how one is interpreted by others. In nearly all studies, it is impossible to say if the 
person with SAD is actually unable to display the adequate behaviour or if he or she 
performs worse due to debilitating anxiety. Accordingly, some authors have suggested 
the term performance deficit when referring to the type of behaviours normally 
investigated in the studies described in this section [97].  
 
Another important aspect of the role of social skills deficits in the development of SAD 
is whether they constitute a cause or an effect of SAD. Several SAD theorists, such as 
Rapee & Spence, suggest that it might be both [98]. That is, for some individuals skills 
deficit may have a direct impact through early aversive social experiences and for 
others skills deficits could evolve over time due to avoidance behaviours thereby 
developing into a maintaining factor.       
 
1.3.4 Neurobiological aspects 
Located in the limbic system of the brain, the amygdala has been found to play a 
central role in the neurocircuitry of fear [99]. Using imaging techniques such as 
positron emission tomography (PET) and functional magnetic resonance imaging 
(fMRI), a large number of studies have shown that SAD is associated with 
hyperreactivity of the amygdala during exposure to social threat stimuli [100-104]. 
Even more relevant to the understanding of neurobiological processes of SAD and its 
treatment, one study used a design where participants with SAD were examined using 
PET before and after treatment with CBT [105]. Participants were randomised to either 
CBT, citalopram or a waiting list control (WLC). The results showed that the active 
treatments were superior to WLC and those who received CBT and citalopram had a 
significantly larger decrease in amygdala reactivity during an anxiogenic public 
speaking task [105].  
 
On a molecular level, several transmittor systems including the dopaminergic, 
serotonergic and glutaminergic have been proposed to play a role in the aetiology and 
treatment of SAD. Using resting state examinations, SAD has been associated with 
lower striatal dopamine 2 (D2) binding potential compared to healthy controls, 
suggesting a structural neuroanatomical marker of SAD [106, 107]. As for the 
serotonergic systems, the accumulated evidence for effect of selective serotonin 
reuptake inhibitors (SSRIs) for SAD clearly indicates that the serotonergic system is 
involved in the regulation of social fear [108]. 
 
In summary, the limbic system and amygdala in particular seem to constitute a central 
neurobiological route for expressing, acquiring and extinguishing anxiety in SAD. 
However, what is being observed in the studies described is the biological footprint of 
expression of anxiety. Thus, it is not reasonable to claim that for example 
hyperreactivity of the amygdala aetiologically causes SAD as it could merely be a 
consequence of other causative factors. Until further prospective data is collected, 
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neurobiological phenomena could probably best be viewed as mediators of causal 
factors of SAD. 
 
1.3.5 Cognitive behavioural models 
Cognitive behavioural models of psychiatric disorders have their historical roots in 
behaviour therapy beginning in the early 1960’s [109] and can be viewed as an 
integration of cognitive and behavioural paradigms. In short, the cognitive behavioural 
model differs from the behavioural in that it not only relies on learning theory but also 
assumes that behaviour change could be mediated by cognitive processes [110]  The 
reasons for adding cognitive processes to behavioural modals were several, such as a 
difficulty of accounting for complex human behaviour including language with 
respondent and operant conditioning [110, 111].  
 
In the following section, I will begin by describing an aetiological view of SAD based 
on a learning perspective followed by a cognitive perspective. Finally these two 
perspectives are integrated in the two most validated and disseminated cognitive 
behavioural models of SAD, developed by Heimberg & Rapee [9] and by Clark & 
Wells [112]. 
 
1.3.5.1 Learning theory 
There are two major behavioural principles constituting the core of learning theory,  
respondent and operant conditioning. Respondent conditioning is the process of 
associating neutral stimuli with unconditioned stimuli, producing conditioned responses 
of the previously neutral stimuli similar to those of unconditioned stimuli [113]. The 
unconditioned stimulus-response pattern refers to basic innate biological processes or 
reflexes, where the fear response is of undisputed importance to survival.  
 
Figure 1 shows the process of fear acquisition by respondent conditioning. The first 
documented experiment of fear acquisition in man was conducted in 1920.  In that 
study, Watson and Rayner demonstrated that a 9-month old boy, Albert, could be 
learned to be afraid of pets by being presented to dogs and rabbits 
(neutral→conditioned stimuli) while exposed to loud noises (unconditioned stimuli) 
[114]. As for SAD, the respondent model assumes that social situations have been 
associated with unconditioned fear stimuli, e.g. humiliation, violence, or exclusion 
from peers.  
 
Few studies have investigated this hypothesis using SAD samples and the results have 
been inconclusive. In a clinical sample of patients with SAD, Öst and Hugdahl found 
that 58% reported a conditioning experience and 13% a vicarious learning experience 
(indirect conditioning) as a trigger of SAD [115]. More recently, one study found that 
56% of persons with non-generalised SAD reported a traumatic social episode prior to 
SAD onset [116]. This was slightly higher than for the group with generalised SAD 
(40%), possibly indicating a differential pathway to SAD for the two subgroups. At 
first glance, a study by Hofmann and co-workers seems to support these findings as 
89% of a sample of persons with pure public-speaking SAD stated that they had had 
experienced direct aversive social conditioning [117]. However, only 15% reported that 
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SAD was developed at about the same time, and the average time until SAD onset was 
21.5 years. In summary, there is some indication that conditioning is involved in the 
development of SAD. Important to bear in mind is that absence of remembered 
aversive conditioning experiences not necessarily constitutes a logic falsification of the 
hypothesis as conditioning is a phenomenon that is independent of conscious  
processing [118]. Needed are studies with objective assessment of conditioning 
processes. 
 
 
Figure 1. A respondent conditioning paradigm of social anxiety 
Abbreviations: UCS, unconditioned stimulus; CS, conditioned stimulus; NS, Neutral stimulus;  UCR, unconditioned 
response; CR, conditioned response 
 
The second major learning principle important for the aetiology of SAD is operant 
conditioning. Operant conditioning refers to the process of learning through 
consequences of behaviour [113]. The three basic elements are discriminative stimuli, 
behaviour and reinforcing/punishing stimuli According to this perspective, central 
behavioural features of SAD, e.g. avoidance of social situations could have evolved 
through consequential conditioning by preventing the occurrence of aversive events, 
i.e. negative reinforcement. Often respondent and operant conditioning are 
interdependent, i.e., the discriminative stimulus could be a conditioned stimulus 
eliciting a conditioned response (e.g. anxiety), which is escaped and negatively 
reinforced through a decrease of the conditioned response, i.e. reduced fear [113]. This 
type of process is likely to serve a maintaining function of social anxiety as avoidance 
behaviours prevents, or at least, retards extinction of the conditioned stimulus.  
 
Several studies of early risk factors of SAD indicate the potent effect of avoidance. For 
example, children with SAD live in families that are less involved in social activities 
[119] and have parents that are more likely to enhance avoidance through 
overprotection [120, 121]. Avoidance of social situations, even if it is not maintained 
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by reduction of conditioned anxiety might be problematic as conditioning of fear is 
more effective in novel situations. This phenomenon is called latent inhibition [122] 
and means that having more experience of social situations attenuates the anxiety 
conditioning if traumatised in a social situation. A final empirical finding indicating the 
role of avoidance in SAD is the result of a large prospective study which showed that 
avoidance of social situations predicted maintained SAD at follow-up [123].  
 
1.3.5.2 Cognitive biases in the aetiology of SAD 
According to cognitive theory, information processes play a pivotal role in the 
development and maintenance of SAD [124]. Several cognitive factors have been 
implied in the aetiology of SAD, such as biased attentional processes, exaggerated 
belief in the probability and costs of negative social events, as well as distorted memory 
processing after social events [125]. Regarding attentional processes, studies using dot-
probe and modified stroop tests have indicated that persons with SAD have an 
attentional bias to threat. For example, Asmundson and Stein found that persons with 
generalised SAD were quicker to respond following cues expressing social threat than 
to cues signalling physical threat or after neutral stimuli [126]. This pattern was not 
seen in healthy controls and the results indicate a disorder specific attentional bias.   
 
In the area of estimation of the likelihood of negative events and their costs, one study 
investigated how persons with SAD interpreted ambiguous social and non-social 
situations [127]. The results showed that persons with SAD had an increased 
probability of interpreting social events negatively [127]. Interestingly, this was only 
the case when picturing oneself in the situation and not when imagining a typical 
person, suggesting that the bias does not concern a general overestimation of the danger 
of social events but that is specific to oneself. The tendency to interpret social events 
negatively has also been reported in studies investigating performance. For example, 
Rapee and Lim and Voncken and Bögels found that, during public speaking tasks, 
persons with SAD underestimated their performance compared to control participants 
[92, 93].  
 
When it comes to biased memory processes, it has been proposed that selective 
memory of threatening information could play a role in SAD. However, as pointed out 
by Henrichs and Hofmann, the evidence of a memory bias in clinical samples is 
limited, perhaps suggesting that information is processed differently depending on the 
phase of the social interaction [124]. An increased attention in the initial phase 
followed by avoidant strategies might explain the seemingly illogical finding that 
attentional biases are poor reflected in memory processes [124]. Importantly, as few 
studies have been conducted caution in drawing conclusions is warranted. 
 
1.3.5.3 Two integrative cognitive behavioural models of SAD  
The cognitive behavioural models proposed by Clark and Wells, and Heimberg and 
Rapee, respectively, are the most validated and clinically used [112, 128]. As the two 
models are similar and share many features, this section presents the Clark and Wells’ 
model in detail, followed by a presentation of how the Heimberg and Rapee model 
differs. An important shared feature of the models is their focus on maintaining factors 
rather than aetiological factors of SAD. 
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The Clark and Wells model is based on the idea that persons with SAD develop 
assumptions about themselves and others (e.g. I’m boring and must be extremely 
friendly to prevent being rejected) that increases the risk of interpreting social events as 
threats. Once a situation has been evaluated as dangerous the processes of self-focused 
attention, in-situation safety behaviours, anxiety induced performance deficits and pre-
and-post event ruminating contribute to maintaining SAD.  
 
Figure 2 shows the model and the proposed relations between the different parts. When 
interpreting a situation as socially threatening, a person with SAD directs attentional 
resources towards himself while perceiving himself as a social object. This has several 
important consequences. To begin with, interoceptive attention makes it easier to detect 
anxiety symptoms that otherwise would have gone unnoticed. As these symptoms are 
themselves often threatening, e.g. blushing, the detection of them increases anxiety in a 
feed-back loop.  
 
Figure 2. A cognitive behavioural model of social anxiety disorder (Clark & Wells) 
 
In addition, interoceptive attention makes it more difficult to use external information 
as markers of how one is perceived. Instead, the pounding heart or trembling hands are 
taken as evidence that one is incapable of handling the situation. To prevent the feared 
disaster from taking place, the model predicts that the anxious person will use safety 
behaviours. This could be nearly anything, from wearing multiple layers of clothing to 
hide sweating from being noticed to drinking alcohol.  
 
These behaviours maintain anxiety for three reasons. First, safety behaviours increase 
interoceptive attention. Second, it is difficult to attain information that contradicts the 
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feared event (e.g. not be able to converse without alcohol) from happening. Third, the 
safety behaviour might actually increase the risk of the feared event (e.g. increased 
sweating due to more clothes).  
  
Besides safety behaviours and attentional biases, a third component is anxiety induced 
performance deficits. This means that the anxiety increases the risk of displaying 
behaviours that could be negatively interpreted by others (e.g. being cold or 
uninterested) and consequently, the person with SAD might be less friendly treated. 
This creates negative interaction patterns and confirms negative beliefs. The model also 
stipulates that persons with SAD are engaged in anticipatory and post-event processing 
meaning that persons with SAD are anxious long before and after the situation has 
occurred, selectively remembering past social failures.  
 
In comparison, the model for maintaining SAD proposed by Rapee and Heimberg 
[128], also stresses the role of the perceived evaluation of others, attention to internal 
and external threat and representation of oneself as a social object. Furthermore, it also 
suggests feed-back loops between behavioural, cognitive and somatic anxiety 
symptoms, attention allocation and risk estimation. The model has a somewhat more 
detailed description as to how anxiety is the product of a comparison of how the 
perceived expectations of the audience and one’s performance match, taking into 
account the probability and cost of negative evaluation.  
 
Superficially, some minor differences exist, for example regarding safety behaviours 
and the role of assumptions. However, on closer examination, the model by Rapee and 
Heimberg uses the term behavioural symptoms to describe safety behaviours in the 
same sense as the Clark and Wells model. In addition, the originators state that the 
model owes much to the thinking behind the Clark and Wells model [128]. The 
similarity between the models is also acknowledged by Clark and Wells [125]. 
  
1.3.6 Concluding remarks on the causes of SAD 
As proposed by Rapee and co-workers and by Ollendick and Hirshfeld-Becker, it 
would be highly unlikely to expect to find a single pathway to SAD based on the risk 
factors presented above [73, 128]. Instead, it is more probable that many combinations 
of factors might lead to SAD [73] and that social anxiety is largely a continuous 
variable where SAD constitutes a certain cutpoint where it becomes clearly debilitating 
[67, 98].  
 
As suggested by SAD theorists, it is reasonable to assume that a common genetic factor 
predispose us to developing a cluster of psychiatric disorders, and in combination with 
at least one other genetic factor, we have a basic degree of social anxiety as a starting 
point [98]. This level of anxiety can be altered through environmental influences. 
However, the greater the discrepancy between anxiety endpoint and starting point, the 
lower the probability. This is because it would require that environmental influences 
would all have to be in the “right” or “false” direction, which would be unexpected 
assuming the central limit theorem holds [129].  
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The pathway to SAD is likely an ongoing interactive process between the person and 
the surrounding environment [73]. For example, a child might have a behaviourally 
inhibited temperament that is largely genetically determined [86]. This might increase 
the probability of having socially anxious parents [130], which in turn could mean less 
exposure to social situations [119] and thereby poorer possibilities to practice social 
skills [95]. When starting school, the child is less socially skilled (need not be anxiety 
driven), which means that he or she is more negatively perceived by other children and 
is less positively rewarded in social interactions [131]. This in turn, increases avoidance 
behaviours, which could further increase the distance to other children in terms of 
capacity to interact with others and perhaps also the risk of being traumatised socially 
(e.g. bullied) [131]. These aversive experiences are in turn likely to have a more severe 
effect than on others due to the latent inhibition effect and the aversive conditioned 
reactions could be maintained by negatively reinforced avoidance or safety behaviours 
[132]. 
 
In order to break this pattern, a potent environmental influence that aims to change the 
level of social anxiety below the cut point for SAD is cognitive behaviour therapy. In 
the following section, the content and structure of the therapy is presented. But first, a 
brief overview of the existing treatment option.      
 
 
1.4 PHARMACOLOGICAL TREATMENTS 
There are two major evidence-based treatments for SAD, pharmacotherapy and CBT. 
Below, a short presentation of pharmacological treatments for SAD is given followed 
by a more detailed description of CBT. 
 
Several pharmacological treatments for SAD have been investigated in RCTs, 
including monoamine oxidase inhibitors (MAOIs) e.g. phenelzine [32, 133], reversible 
inhibitors of monoamine oxidase A (RIMAs), e.g. moclobemide [134] Selective 
serotonin reuptake inhibitors (SSRIs), e.g. paroxetine [135], and Benzodiazepines, e.g. 
atenolol. [32]. Until only about 10 years ago, MAOIs were considered the 
pharmacological treatment of choice for SAD due to its large effects [136]. However, 
because of safety issues, e.g. side effects as sleep disturbances and sexual dysfunction, 
it is today not regarded as the first treatment option [136]. The same reasoning holds for 
benzodiazepines, i.e. the treatment is effective in treating social anxiety, but could be 
less safe not at least due to the risk of developing a physical dependence [137].  
 
Instead, during the last 17 years SSRI has emerged as the treatment of choice because 
of its effectiveness and tolerability. At least 16 placebo controlled double blind trials 
have been conducted investigating the effect of SSRIs for SAD and in the majority of 
those the effect sizes have been in the moderate to large range [138, 139]. If 
discontinuing medication, relapse tends to be the rule rather than the exception, but 
when adhering to treatment gains are maintained at longer term follow-up [139]. 
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1.5 COGNITIVE BEHAVIOUR THERAPY (CBT) 
Aside from CBT, several other psychological treatments have been investigated for 
SAD, including psychodynamic therapy [140], interpersonal psychotherapy [141] and 
more recently, attention training [142]. However, to date, CBT is by far the most 
empirically validated psychological treatment [10]. Reported in a recent review, 
Ponniah and Hollon identified 37 RCTs documenting the effect of CBT for SAD [143]. 
Although CBT covers a broad range of interventions, common to nearly all are the 
components of psychoeducation, exposure to feared social situations, cognitive 
restructuring and relapse prevention [10, 144]. In the following, I will be focusing on 
the CBT developed for individual treatment by Clark and Wells [145] as well as the 
cognitive behavioural group therapy (CBGT) developed by Heimberg and co-workers 
[22]. This is because they are the best studied and disseminated and because they are of 
relevance for the treatments delivered in the empirical studies of the present thesis. 
From this point on, when referring to individual or group CBT, the treatments by Clark 
and Wells and Heimberg and co-workers, respectively, are implied. 
 
1.5.1 Components of CBT 
CBT for SAD is based upon the models presented in the previous section, thus aimed at 
breaking the vicious cycle between anxiety symptoms, catastrophic interpretations, 
attention to internal and external threat, safety behaviours and avoidance behaviours. 
[145]. Common to both individual CBT and CBGT is the formulation of an individual 
conceptualisation of the patient’s problem based on the CBT model. In addition, both 
treatments put a strong emphasis on weekly home work exercises and entail 
psychoeducational components, such as describing the nature of anxiety and the 
rationale for the treatment components. Furthermore, both individual CBT and CBGT 
include exercises where exposure to social stimuli and cognitive restructuring are 
integrated, and finally, both entail relapse prevention.  
 
However, in individual CBT, the exposure exercises have a more specific aim of 
disputing negative thoughts and are typically carried out as behavioural experiments. In 
contrast, exposure during CBGT is carried out with a slightly more habituation oriented 
rationale. Whereas CBGT has a very strong emphasis on exposure combined with 
cognitive restructuring throughout the treatment, individual CBT entails specific 
interventions aimed at displaying the disadvantages of safety behaviours. This is carried 
out through experimental like manipulations of safety behaviours while paying close 
attention to thoughts, anxiety levels and attentional allocation.  
 
In addition, individual CBT includes specific interventions aimed at shifting attention 
from internal focus to the external situation. In CBGT, external focus is encouraged 
during exposure, but there are no specific exercises in this area. In summary, individual 
CBT and CBGT have many vital components in common, but differ in the sense that 
CBGT has a very profound focus on exposure combined with cognitive restructuring, 
whereas individual CBT comprises additional interventions specifically related to 
safety behaviours and attentional shift.   
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1.5.2 Structure of the treatments 
Individual CBT is typically delivered in weekly 1-hour sessions with a single therapist 
for a duration of 14-16 weeks [145-147]. The treatment starts with creating an 
idiosyncratic SAD model, followed by manipulation of safety behaviours, exercises in 
attention shifting, behavioural experiments, strategies for pre and post-event worrying 
and relapse prevention [145-147]. In CBGT, therapy is lead by two therapists and 
usually comprises weekly 2.5 hour group sessions for a duration of 12 weeks [22]. 
Ideally there are 6 patients in the group making a total of 8 persons. Prior to group 
sessions, there is an individual treatment orientation interview where goals are set and 
an individual treatment plan is formulated [22]. This is followed by two sessions of 
psychoeducation and training in cognitive restructuring. After this, sessions 3 through 
11 have a strong focus on in-session exposure exercises whereas the final session is 
devoted primarily to relapse prevention [22].  
  
1.5.3 Effectiveness of CBT for SAD 
CBT for SAD has been evaluated in clinical trials for more than 25 years yielding a 
solid knowledge base. At least four meta-analyses have been conducted specifically 
devoted to cognitive behaviour therapy [148-151]. In a fairly recent meta-analysis, 
Fedoroff and Taylor identified 21 trials investigating the effect of treatments entailing 
exposure and cognitive restructuring. When combining these studies, they found an 
average within group effect sizes of Cohen’s d=0.83 (95% CI, 0.71-0.97) on measures 
of social anxiety, indicating large effects [150]. However, this pre-post design did not 
control for confounders, meaning that it is difficult to attribute the effect to CBT. Using 
a slightly different meta-analytic approach including only studies using control groups, 
Gould and co-workers found that the between group effect size for the 16 studies 
investigating CBT was d=0.74 (95% CI, 0.54-0.94) [151] suggesting that CBT has a 
substantial effect compared to control conditions.  
 
When interpreting this effect size estimate there is one important methodological aspect 
to bear in mind. The quality of the control conditions vary greatly where waiting-list 
controls hardly control for much more than the passage of time, whereas some use 
psychological or pharmacological placebo. Considering this, an interesting finding in a 
meta-analytic study by Taylor and co-workers was that CBT (exposure plus cognitive 
restructuring) was superior not only to waiting list controls but also to placebo [149]. 
Although the empirical support for CBT is strong, important to note is that far from all 
patients achieve remission. Even in the studies yielding the highest average effect sizes, 
only 75% of the patients make substantial improvements [146].  
  
Of specific relevance to this thesis, CBGT is the psychological treatment with largest 
empirical support. It has been investigated in at least 12 RCTs and demonstrated 
superiority over psychological [9] and pharmacological placebo [133, 152]. Individual 
CBT employing the Clark & Wells protocol has been investigated in at least 5 RCTs 
and has proven to be superior to flouxetine, pill placebo [147] and psychiatric treatment 
as usual [153] An important aspect is that CBGT has been investigated in at least seven 
RCTs independent of the originators, whereas I have only found one study following 
the Clark and Wells’ protocol not reported by the originators [154] Although CBGT is 
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the most well-studied intervention, treatments following the Clark and Wells’ protocol 
seem to yield slightly higher effect sizes. The following subsection presents evidence 
regarding the effect of structure (individual or group) on the outcome.  
 
1.5.3.1 Group CBT vs. Individual CBT 
Intuitively, there seem to be many advantages of delivering CBT in a group format, 
some especially important in the treatment of SAD: the group offers a wide array of 
exposure possibilities, and observing the discrepancies between others’ view of oneself 
and one’s actual performance can be used to weakening the belief that anxiety is a valid 
proxy for objective assessment of appearance. However, this hypothesis has limited 
support in the literature.  
 
In a meta-analytic study, all evaluated treatments except social skills training had been 
conducted both as group and individual treatment. Within each treatment stratum, there 
was no significant difference between the two delivery formats [150]. Of course, there 
is always a risk of comparing apples and oranges as the group format most often is not 
the only difference between individual and group CBT. For optimal assessment of the 
effect of delivery format, the best design would be a study that compares the same 
content in different formats. One such a study has been carried out in which 
participants (n=95) were randomly allocated to either individual, group CBT or a 
waiting list control where both treatments were identical content wise (Clark and 
Wells’ protocol) [145]. The results showed that participants receiving individual CBT 
were significantly more improved on the primary social anxiety measure [145]. These 
findings were replicated in a study by Mörtberg and co-workers using a treatment based 
on the same protocol [153]. The authors found that individual CBT was superior to 
group CBT (intensive format) displaying large differences in effect sizes when 
comparing the two types of CBT [153].  
 
Thus, contrary to what could be expected, it might be that the individual format is 
superior to delivering treatment in group. Several explanations have been proposed. It 
might be that the techniques involved in cognitive restructuring are too complex too 
learn in a group format, or perhaps the group format does not allow for the highly 
individualised analyses needed for optimal planning and execution of exposure 
exercises [155]. It could also be that anxiety provoked by the group to some extent 
prevents effective learning when it comes to complex tasks. As Heimberg’s CBGT has 
not yet been compared in this fashion, and the complexity of CBGT is somewhat lower 
compared to the Clark and Wells model, it is not directly possible to claim that this 
holds for CBGT. More studies are needed to clarify the moderating effect of treatment 
content on format and treatment outcome.    
 
1.5.4 Combination of CBT and pharmacological treatments  
With two effective types of treatments for SAD (CBT and pharmacotherapy) yielding 
large effects for some but not for all, a reasonable suggestion is that a combination of 
the two might produce additional effects. I know of 3 RCTs employing a design where 
a combination of pharmacotherapy and CBT (or at least partially based on CBT) has 
been compared to stand alone treatments for SAD [152, 156, 157]. In two trials where 
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monotherapy with CBT and SSRI (sertraline and flouxetin, respectively) was compared 
to a combined treatment, no differences were found between treatments at follow-up 
[156, 157]  
  
In a recently conducted RCT, participants with SAD were allocated to one of four 
groups: CBGT, phenelzine sulfate (MAOI), combined CBGT and Phenelzine, or to 
placebo [152]. The results showed that the combined treatment was superior to both 
monotherapies as well as to placebo.  
  
Important to keep in mind when considering combination treatments for SAD is that 
monotherapies in general are developed to be stand alone treatments. Hence, there is no 
firm theoretical ground to assume strong additive effects. An interesting exception is 
the advancement in the field of combining the partial N-methyl-d-aspartate receptor 
(NMDA) agonist d-cycloserine (DCS) with exposure therapy. The suggested 
mechanism, demonstrated in animal models, is that NMDA-receptor activity of the 
amygdala to some extent mediates the effect of fear extinction and that DCS alters 
NMDA functioning [158].  
 
In the field of SAD, Hofmann and co-workers demonstrated in a small RCT (N=27) 
that participants receiving 50 mg doses of DCS prior to each of four exposure sessions 
made significantly larger improvements (between groups Cohen’s d=0.69-1.42) 
compared to those receiving exposure plus placebo [159]. These findings were 
replicated in a subsequent larger scaled RCT using the same design [160]. Thus, future 
combination treatments for SAD might be more directed towards facilitating extinction 
learning rather than combining treatments designed to work as monotherapies. Future 
studies need to address if the additive effects of DCS are maintained when using the 
full CBT treatment. 
 
1.5.5 Determinants of treatment outcome 
As stated above, a substantial proportion (25-50%) of those receiving treatment do not 
respond sufficiently well to treatment [133, 145, 152]. Under these circumstances, 
identification of outcome predictors and moderators could facilitate: a) reduced dropout 
rates and number of treatment failures [161, 162], and b) individually tailored 
treatments [161, 163]. In RCTs, a predictor is a baseline or posttreatment variable that 
has a main effect on outcome but no interactive effect with treatment condition. A 
moderator specifies for whom or under which conditions a treatment works [164]. 
More specifically, in RCTs a moderator is a prerandomisation characteristic that has an 
interactive effect with treatment condition on the outcome [161]. Previous research on 
CBT for anxiety disorders has identified three general categories of predictors: patient 
demographics including personality traits, clinical characteristics, and therapy process 
variables [163, 165, 166]. In addition, there is a growing body of evidence supporting 
the role of genetic factors when predicting outcome of treatment with SSRIs for SAD 
[81]. 
 
In terms of patient demographics, employment and marital status have been found to be 
predictors of outcome in CBT for depression and GAD, and for the course of untreated 
anxiety disorders [167-169]. When it comes to clinical characteristics, higher symptom 
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levels, age of onset, comorbid depression and avoidant personality disorder have been 
suggested to be predictors of treatment outcome following conventional CBT for SAD 
[170, 171]. In the category of therapy process predictors, expectancy of treatment 
outcome and treatment adherence have been shown to predict treatment response [172, 
173]. Overall, the predictors above fit well onto the CBT-model for SAD, whose 
proposed mechanism of change is reduced social anxiety by altered cognitions and a 
reduction of conditioned fear as a result of repeated exposure [22, 112]. Thus, having 
more social resources and attending therapy could be associated with greater 
possibilities to expose to social situations.  
 
The fourth and clearly least studied general category of predictors is genetic factors. 
Allelic variation in the serotonin transporter gene promoter (5-HTTLPR) has been 
associated with treatment response of SSRI for SAD [81], panic disorder [174] and 
depression [175]. There is, to my knowledge, only one published study on the 
association of gene polymorphisms and CBT [176]. In that study, the 5-HTTLPR 
polymorphism affecting the expression of the serotonin transporter was associated with 
outcome of CBT for PTSD.  
 
More recently, a functional polymorphism in the catechol-O-methyltransferase gene 
(COMTval158met) has been associated with limbic activation during exposure to 
unpleasant stimuli [82]. COMT is an enzyme that catalyses the degradation of 
catecholamines neurotransmitters such as dopamine and the effect of the 
COMTval158met is suggested to be mediated by up to a four-fold variation in enzyme 
activity [82]. A third candidate polymorphism is the brain derived neurotrophic factor 
(BDNFval66met) gene. Met-carriers of the BDNFval66met have been shown to have 
impaired ability in extinguishing conditioned fear responses [177], which suggests that 
it could play a role in CBT for SAD. No published study has yet investigated the 
predictive effect of these three gene polymorphisms in the treatment of CBT for SAD. 
 
I have found no studies suggesting stable moderators when comparing different forms 
of CBT for SAD. As the suggested mechanism of change is the same regardless of 
whether treatment is delivered face-to-face or, pertinent to this thesis, via the Internet, 
there are few apparent moderating variables. Although the Internet-based CBT 
employed in this thesis is simple as it entails no advanced features, it might be that 
computer skills would moderate the treatment effect. This has not been investigated 
when pitting Internet-based CBT against conventional CBT, but is important as a 
warranted question is whether CBT delivered via the Internet is suitable for the average 
patient or only for those highly skilled in computer use. 
 
When assessing predictors and moderators, an important methodological aspect to 
consider is which dependent variable one tries to foresee. That is, it might be that 
predictors have different impact on end state symptom severity as compared to 
symptom change. Accordingly, in a recent review of predictors on outcome of CBT for 
SAD, Eskildsen and co-workers found that comorbid depression and avoidant 
personality disorder predicted end state functioning (more symptoms), but to a much 
lesser degree, improvement [171]. Although power in that study was limited, it might 
be that CBT works equally well across initial symptom levels in terms of change, but 
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that those with high initial anxiety levels tend to have higher levels at posttreatment 
compared to those with lesser symptom burden.  
 
However, as pointed out by several, change is difficult to assess [178]. For example, 
using change of raw scores might overestimate the change effect of extreme scorers, 
whereas percent change scores tend to overestimate the effect of low scorers, e.g. a 
change from 4 to 2 on the Montgomery-Åsberg Depression Rating Scale constitutes a 
50% reduction while a clinically more relevant change from 35 to 19 is a mere 46% 
reduction [178]. Therefore, the use multiple outcome definitions and the use of 
regression models with untransformed criterion variable scores and first entrance of 
preassessment scores has been proposed [171, 179], yielding similar effects as the 
somewhat less intuitive residual gain score approach [178].  
 
In summary, several demographic, clinical, therapy process related, clinical, and 
genetic factors have been suggested to affect outcome of CBT for SAD. However, there 
is yet no evidence of the predictive or moderating effect of these variables when 
comparing conventional CBT to Internet-based CBT.    
  
1.5.6 Availability of CBT 
As CBT is a treatment that has existed for only about 25 years and simultaneously has 
demonstrated effectiveness for a wide range of psychiatric disorders, the demand of 
CBT has for a long time been exceeding the supply [180]. Consequently, the 
availability to CBT is limited for many of those suffering for anxiety disorders such as 
SAD. Several factors contribute to the lack of availability such as a lack of properly 
trained therapists and high costs for the patient when buying CBT on the private 
market. In rural areas in countries with low population density such as the United 
States, Australia, Canada and Scandinavian countries, long distances might severely 
restrict availability. In a study by Shapiro and co-workers, the availability of CBT in 
England and Wales was investigated and the results showed that conventional CBT is 
available for about 1% of those suffering from anxiety disorders and depression [11]. 
An important finding was that the geographic inequities were substantial as there were 
up to 20 times more CBT therapists per 100 000 inhabitants in the 10th population 
decile (highest availability) compared to the 1st [11].  
 
1.5.7 The need for CBT 
As the availability to CBT is limited and pharmacotherapy, especially SSRIs, have 
been shown to be effective in the treatment of SAD, a reasonable question is whether 
dissemination of CBT is important. Why not just increase the proportion of patients 
treated pharmacologically? As a matter of fact, several aspects of CBT make it an 
advantageous treatment. First, a substantial proportion of patients receiving 
pharmacotherapy experience adverse side effects such as insomnia, weight gain or 
altered blood pressure [137, 152]. Second, for some patient groups, pharmacotherapy is 
counter-indicated because of potential safety issues. Third, CBT seems to produce 
enduring effects even in the absence of maintenance treatment [10], while relapse is 
common if discontinuing pharmacological treatments [139]. Finally, CBT might be the 
treatment of patient preference for persons with SAD. Although I have found no 
   25 
published studies on SAD samples, articles reporting preferences among patient groups 
with depression and health anxiety have found preference ratios of 3:1 and 18:1 in 
favour of psychological treatments compared to pharmacotherapy [181, 182]. In 
conclusion, several important factors suggest that increasing availability to CBT is a 
crucial objective for psychiatric health care providers. 
 
1.6 INTERNET-BASED CBT (ICBT) FOR SAD  
Although the face-to-face encounter is the typical context for psychological treatments, 
other ways of delivering therapy has been available for more than 35 years [183].  The 
most widely used alternative method is probably bibliotherapy. Bibliotherapy can be 
described as a treatment delivered in form of a self-help text with a clear aim of solving 
problems relevant to a person’s therapeutic needs [184]. By the time of conducting 
Study I of this thesis in 2005, no study had been published study on bibliotherapy with 
CBT for SAD. However, since then at least three RCTs have been published 
demonstrating moderate to large effects of CBT delivered as bibliotherapy for SAD 
[185-187]. 
 
With the advent of personal computers and the Internet a new modality of delivering 
CBT has been made possible - Internet-based CBT (ICBT). CBT delivered via the 
Internet has been around for just a little longer than 10 years, but has already been 
found efficacious for a plethora of psychiatric disorders such as panic disorder, major 
depression, eating disorders and general anxiety disorder [12]. Very recently, 
colleagues in my research group and I published the first RCT demonstrating efficacy 
of ICBT for severe health anxiety [188]. Another interesting venue of ICBT research is 
in the area of irritable bowel syndrome [189, 190]. 
 
When referring to treatments facilitated by computers, important to remember is that 
there is a wide range of treatments with great variability both in terms of therapist-
guidance and technical complexity. The former parameter can vary from no contact at 
all (e.g., just a CD-ROM programme) to therapy conducted through video conferencing 
yielding just as much live therapist contact as in conventional CBT [191]. As for 
technical complexity, some treatments rely on specifically designed hard ware enabling 
virtual reality exposure exercises [192] whereas others rely heavily on online text [13]. 
In the studies included in the present thesis, the type of ICBT employed and referred to 
if not otherwise mentioned, follows a structural model originally developed by Ström 
and co-workers for the treatment of headache [193].  
 
This type of ICBT can essentially be described as guided online bibliotherapy with 
therapist contact through an Internet-based messaging system resembling e-mail. Thus, 
the treatment comprises few advanced technical features, is text-based and therapist 
contact is restricted to online messages that are not in real-time. Content wise, the 
treatment follows the Clark and Wells’ CBT-model developed for individual therapy 
presented above [112]. A vital part of the treatment is the gradual access to an online 
self-help text comprising 15 modules, each covering a specific theme (e.g., exposure or 
cognitive restructuring) completed with a homework component. Table 3 presents the 
main theme of each module.  
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The general idea of the treatment is that the modules should provide the patients with 
the same knowledge and tools as conventional CBT for SAD. The role of the therapist 
is mainly to provide feedback regarding home work and to grant access to the treatment 
modules, thereby often not using more than 5-10 minutes weekly per patient [12]. 
However, the patient can contact the therapist at any time and expect a reply within 24 
hours during weekdays. Throughout the treatment, patients have access to an online 
discussion forum where they can communicate anonymously with other patients 
receiving ICBT for SAD. 
 
In addition to these main features, several components integrated in the treatment 
platform facilitate treatment delivery. These include Internet-based work sheets and 
automatic generated alerts when the treatment deviates from the expected course. For 
example, this could be when the patient has not logged in for seven days or takes too 
long when it comes to sending in homework exercises. Furthermore, symptom 
assessment can be conducted online as the Internet has been shown to be a valid format 
of administrating self-report questionnaires [194]. This is important from a safety 
aspect as it enables a secure form of monitoring of patients’ depressive symptoms as 
algorithms for automatic alerts can be programmed making sure that therapists are 
aware if patients’ scores are indicative of risk for suicidal behaviours.    
 
Table 3. Content of the modules of ICBT for SAD. 
 
 
Module 
 
Main theme 
Number of 
pages 
1 Introduction, information on CBT and SAD 19 
2 A CBT-model for SAD 20 
3 Cognitive restructuring, part I 30 
4 Cognitive restructuring, part II 4 
5 Behavioural experiments 24 
6 Exposure, part I  24 
7 Exposure, part I continued 2 
8 Exposure, part I continued 2 
9 Safety behaviour manipulation, part I 19 
10 Safety behaviour manipulation, part II 2 
11 Exposure, part II 17 
12 Exposure, part II continued 2 
13 Psychoeducation on assertiveness 19 
14 Summary and relapse prevention 16 
15 Relapse prevention 6 
 Total number of pages 246 
Abbreviations: CBT, cognitive behaviour therapy; SAD, social anxiety disorder 
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1.6.1 Treatment mechanisms of Internet-based CBT for SAD 
So, how it is possible that a treatment delivered via the Internet could work? There are 
several misconceptions when it comes to the treatment of ICBT, not seldom 
contributing to a slight degree of skepticism towards the treatment [12]. First of all, 
ICBT for SAD does not mean that one occasionally visits a public webpage to get 
general advice on how to handle anxiety. On the contrary, ICBT is delivered in a 
strictly regulated health care context with thorough diagnostic assessment making sure 
that one receives a treatment specially adapted for SAD. This means that neither the 
patient nor the therapist is anonymous and that the therapist has the same amount of 
treatment responsibility as in regular health care. A second important point is that a 
good therapeutic alliance can be established online and evidence suggests that the 
access to a therapist might be crucial to yield strong treatment effects [195, 196]. In 
fact, a meta-analysis by Spek and co-workers showed that the most effective computer-
based treatments for anxiety and depression were those with therapist support [196].  
 
A third vital feature of ICBT for SAD as presented in this thesis is that it is not 
something that primarily takes place on the Internet. Instead, the major mechanism of 
effect is reduced social anxiety by demanding behaviour change according to CBT 
principles. Thus, the Internet is a new modality of delivering CBT, and if patients do 
not engage in repeated structured exposures to social situations, no improvement is 
expected.  
 
1.6.2 Advantages of Internet-based CBT for SAD 
There are several important positive aspects of Internet-based CBT. As it is 
independent of distance between therapist and patient, treatment can be facilitated in 
remote low density populated communities. In addition, as there is no real time contact, 
therapist and patient can work with the treatment at time points where it is best suited, 
making the process of treating SAD more efficient for both parties. A specific issue 
often arising in outpatient clinics is that, even if the patient is willing to put several 
hours per week into the treatment, it could be difficult to get time off from work. 
Compared to individual CBT, this is even more problematic when conducting group 
therapy as it means that patients have to take at half a day off weekly for at least three 
months. This problem never occurs in Internet-based CBT. From a research 
perspective, ICBT has several advantages. One major is that the firm structure enables 
high control over the treatment content that the patient is exposed to, making it an ideal 
delivery format for comparing different treatments.  
 
Finally, perhaps the most important advantage relevant to clinical practice concerns 
availability. As the therapist spends only around a fifth of the time per patient compared 
to conventional CBT, each therapist can treat 4-5 times more patients enabling an 
increased availability to psychological treatment [12]. In addition, as outlined below in 
the following section, this feature of SAD makes the treatment potentially very cost-
effective. 
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1.6.3 Cost-effectiveness of Internet-based CBT for SAD 
As health care resources are limited, Swedish legislation stipulates that a governing 
principle in the recommendation of subsidies of health care interventions should be 
cost-effectiveness [197]. Cost-effectiveness analysis is a tool for estimating the 
summarised expected benefits, harms and costs of implementing a new treatment into 
clinical practice [198]. It is a combined measure of the incremental costs and effects of 
a treatment compared to an alternative, such as another treatment or a waiting list 
control.  
 
The result of a cost-effectiveness analysis is usually presented as the ratio of the net 
costs to net health benefits between two alternatives, yielding a so called incremental 
cost-effectiveness ratio (ICER) [198].  Thus, a treatment producing stronger effects to a 
lower cost is always considered cost-effective, whereas a treatment can differ in 
effectiveness and be regarded cost-effective depending on the willingness to pay for a 
better outcome.  
 
Typically, a cost-effective analysis adopts either a disorder specific outcome, such as 
no longer having the SAD diagnosis, or the more generic outcome of quality adjusted 
life years (QALYs). In the latter case, the analysis is called cost-utility analysis where a 
QALY of 1 is equivalent with one year of full health and score of 0 equivalents death. 
Thus, four years lived with a quality of life of 0.25 yields a total QALY of 1 [199]. The 
result of a cost-effectiveness analysis or cost-utility analysis can be interpreted as the 
price that has to be paid in order to achieve an additional case of remission from SAD 
or an additional year in full health. A treatment in itself can never be defined as cost-
effective, as stated above it is always cost-effective in relation to an alternative and in 
relation to the willingness to pay for an additional improvement. Depending on health 
care resources and disease, the latter varies. In industrialised countries, a new treatment 
that yields an additional QALY for less than €50 000 is typically considered cost-
effective [200, 201] 
 
When conducting cost-effective analyses, one can either adopt a health care provider or 
a societal perspective. In the former case, only direct costs of treatment are considered 
whereas all costs including productivity loss are included the latter. It has been 
suggested that the societal perspective is superior as it does not favour any special 
interest [202]. In addition, as the large economic impact of SAD pertains indirect costs, 
it is reasonable to adopt a societal perspective [70].  
 
In one study investigating the cost-effectiveness of treatments for SAD it was found 
that conventional CBT (CBGT) seemed to be the least costly intervention compared to 
conventional CBT and pharmacotherapy with SSRIs over a two year period [151].       
 
As ICBT requires a limited amount of therapist resources, [12, 203], it has the potential 
of being a more cost-effective treatment than CBGT. This, in turn, could enable a more 
optimal health care resource allocation thereby increasing accessibility to CBT and 
reducing wait times. In a study by Titov and co-workers, ICBT has been estimated to 
be less costly than CBGT and equally effective in reducing symptoms [204]. However, 
although pioneering work, Titov and colleagues used estimates partly based on 
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previously published data from an independent study and differences between 
treatments were indirectly estimated. In addition, the analysis was based on the cost of 
the intervention only, not considering other medical and non-medical costs which 
constitute the major part of the societal economic burden of SAD.  
 
To my knowledge, no study has prospectively investigated the cost-effectiveness of 
ICBT for SAD compared to conventional CBT from a societal perspective.  
  
1.7 FROM DEVELOPMENT TO CLINICAL IMPLEMENTATION 
For more than 20 years, there has been a debate as to whether the results of controlled 
treatment research can be generalised to regular clinical settings [205]. The terms 
efficacy and effectiveness have been used to denote different kinds of research 
approaches where the former refers to research focused on high internal validity and the 
latter on scientific work yielding high external validity [206]. That is, in order to 
demonstrate a treatment’s efficacy it is necessary to establish control over potential 
confounding variables. To prove a treatment’s effectiveness means demonstrating that 
it works in circumstances resembling clinical routine practice.  
 
Several aspects of efficacy trials have been proposed to reduce generalizability. These 
include using exclusion criteria that limit the variability of the sample, random 
allocation to treatment interventions, and the use of specifically trained therapists and 
assessors who are motivated by research interests [205]. Ideally, in effectiveness trials 
there is no trade-off between internal and external validity. This means they should 
fulfil all criteria for efficacy research while simultaneously showing that a treatment 
works in real-world conditions [206]. When a treatment has been shown to be 
efficacious, effective, health economically evaluated and possible to administer on a 
large scale, it can be viewed as suitable for dissemination [206]. 
 
By the time of finishing Study I of the present thesis, there were only two published 
randomised trials, both conducted at Uppsala University in Sweden, in the field of 
ICBT for SAD [13, 14]. In the first published study, conducted by Andersson and co-
workers, ICBT was combined with two 3-hour exposure sessions in an RCT and the 
results showed a large effect of the treatment  [13]. In a subsequent study following the 
same model but omitting the exposure sessions, while adding weekly supportive 
telephone calls, the strong effects were maintained  [14].  
 
Thus, when conducting study I of this thesis, ICBT for SAD seemed to be a promising 
treatment option, but neither efficacy nor effectiveness was established. Several highly 
important aspects remained to be investigated and I deemed the following to be the 
most pivotal:  
 
a) Is ICBT  for SAD efficacious when administered without additional live 
exposure sessions or weekly phone calls,  
b) Is ICBT for SAD feasible and effective when delivered in a psychiatric setting,  
c) Is ICBT  for SAD long-term effective,  
d) Is ICBT for SAD cost-effective compared to conventional CBT, 
e) Is it possible to identify determinants of treatment outcome of ICBT for SAD?  
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Since then, i.e. in the last five years, there has been vast increase in research in the field 
of ICBT for SAD. In addition to the work conducted by my research group, Titov and 
co-workers in Austalia have made highly valuable contributions to the field as have 
Berger and colleagues in Switzerland. [13, 14, 186, 207-217].  
  
The studies included in this thesis have been part of a research development 
contributing to the goal of bridging the gap between the experimental setting and 
clinical practice, thereby taking ICBT from a promising idea to an accessible treatment. 
Starting in a lab setting and finishing in an Internet Psychiatry Clinic, the studies of this 
thesis reflect the maturation process of ICBT for SAD. In other words, they have been 
an important part of the journey from efficacy to effectiveness. 
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2     AIMS OF THE THESIS 
 
The general aim of the present thesis was to investigate clinically relevant effects of 
Internet-based cognitive behaviour therapy (ICBT) for social anxiety disorder (SAD). 
Specific aims, presented under the corresponding study, were the following:  
 
Study I 
I. To investigate the efficacy of ICBT compared to bibliotherapy and a waiting list 
control condition in the treatment of SAD. It was hypothesised that ICBT and 
bibliotherapy would be superior to a waiting list control condition in reducing social 
anxiety. In addition, ICBT was expected to be superior to bibliotherapy. 
 
Study II 
II. To investigate the effectiveness of ICBT SAD compared to the most well-
established psychological treatment for SAD – cognitive behavioural group therapy 
(CBGT) - when administered in a clinical setting. It was hypothesised that ICBT would 
be at least as effective as CBGT in reducing social anxiety. 
 
Study III 
III. To investigate whether ICBT for SAD is long-term effective. It was hypothesised 
that treatment gains in terms of reduced social anxiety would be maintained five years 
after receiving therapy. 
 
Study IV 
IV. To investigate the cost-effectiveness of ICBT for SAD compared to CBGT from a 
societal perspective. It was hypothesised that the treatments would generate significant 
and equivalent societal cost reductions. In addition, ICBT was expected to be more 
cost-effective than CBGT due to lower costs of treatment and equivalent treatment 
effects. 
 
Study V 
V. To investigate clinical, demographic, therapy process related and genetic predictors 
and moderators of ICBT and CBGT. It was expected that variables indicating strong 
social support, less psychiatric comorbidity, treatment adherence and receiving the 
preferred type of CBT would predict treatment response. In addition, it was 
hypothesised that non S-allelic carriers of the serotonin transporter gene promoter  
(5-HTTLPR) polymorphism, and non-met allelic carriers of the catechol-O-
methyltransferase (COMTvalmet158) and the brain derived neurotrophic factor 
(BDNFval66met) gene polymorphisms would have a superior treatment response. 
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3 THE EMPIRICAL STUDIES 
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3.1 STUDY I. EFFICACY OF INTERNET-BASED COGNITIVE 
BEHAVIOUR THERAPY AND BIBLIOTHERAPY FOR SOCIAL 
ANXIETY DISORDER: A RANDOMISED CONTROLLED TRIAL 
 
3.1.1 Context and aims 
Two previous trials have demonstrated that Internet-based cognitive behaviour therapy 
(ICBT) might be an efficacious treatment for social anxiety disorder (SAD) [13, 14]. 
Those studies employed additional therapist support, either through live exposure 
exercises or through weekly telephone calls. However, to date, ICBT in this online only 
form has not been validated in a randomised controlled trial (RCT). In addition, an 
important question is how the treatment works when presented as bibliotherapy (BIB), 
i.e. as a self-help book without additional therapist guidance. A recent trial showed only 
limited efficacy of pure self-help [185] for SAD although this form of treatment has 
been successful for other disorders [218]. The aim of the present study was to 
investigate the effect of ICBT and bibliotherapy compared to a waiting list control 
condition (WLC).  
 
3.1.2 Methods 
3.1.2.1 Trial design 
This was a randomised controlled superiority trial within the context of a parallel group 
study with randomisation in 1:1:1 ratio. 
 
3.1.2.2 Recruitment and participants 
All participants were recruited through self-referral. To be eligible for inclusion, 
participants had to meet the following main criteria: (a) have a primary diagnosis of 
SAD although allowing for comorbid psychiatric disorders (b) score <31 on the 
Montgomery Åsberg Depression Rating Scale self-report [MADRS-S; 219] and <4 on 
the suicide item of the same scale; (c) not undergo any other psychological treatment 
during the study period; (d) if on prescribed drugs for anxiety/depression, have a 
constant dosage for 3 months before treatment onset and unchanged throughout the 
study; (e) be at least 18 years old. SAD diagnosis was established using the research 
version of the Structured Clinical Interview for DSM-IV axis-I disorders [SCID-I-RV; 
220]. Of the 342 individuals who applied to participate, 120 fulfilled all criteria and 
were randomised to either ICBT (n=40), BIB (n=40) or WLC (n=40). The sample 
comprised 81 women (67.5%) and 39 men (32.5%), and the mean age was 36.1 years 
(SD=10.5).  
 
3.1.2.3 Outcome measures  
Four social anxiety questionnaires were used as primary outcome measures: the 
Liebowitz Social Anxiety Scale self-report version [LSAS-SR; 221], the Social Phobia 
Scale [SPS; 222], the Social Interaction Anxiety Scale [SIAS; 222], and the Social 
Phobia Screening Questionnaire [SPSQ; 8].  In addition, three secondary measures 
were used to measure general anxiety, depression and quality of life, respectively: the 
Beck Anxiety Inventory [BAI; 223], the MADRS-S and the Quality of Life Inventory 
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[QOLI; 224]. All instruments were administrated via the Internet at pre-treatment 
(baseline), post-treatment and one-year follow-up. Participants filled out the LSAS-SR 
every week in order to monitor weekly treatment gains. 
  
3.1.2.4 Treatments 
3.1.2.4.1 Internet-based cognitive behaviour therapy 
This consisted of the Internet treatment for SAD as outlined in the introduction of the 
thesis. Main components were the self-help manual, weekly e-mail feedback from an 
Internet therapist, and an online discussion forum. The duration of the treatment was 
nine weeks. Therapists were three licensed psychologists and two clinical psychology 
students in the final semester of the master’s degree programme. 
 
3.1.2.4.2 Bibliotherapy 
These participants received the complete self-help manual for social anxiety disorder 
by mail together with an explanatory letter with instructions to complete one module 
per week, and to fill out the LSAS-SR form online. The manual was thus the same as 
the one used for ICBT with only minimal changes to the text regarding homework 
assignments. Participants had no contact with the study team except for the usual online 
assessments before, immediately after and one-year after treatment. The duration of the 
treatment was nine weeks. 
 
3.1.2.4.3 Waiting list control  
Participants in this group had no contact with each other or with the study team during 
their waiting period except for reminders via e-mail or SMS to complete the weekly 
LSAS-SR assessment. Immediately following the waiting period participants were 
crossed over to ICBT. 
  
3.1.2.5 Statistical analysis 
Differential outcomes were evaluated at post-treatment and follow-up by analysis of 
covariance (ANCOVA) using pretreatment values as covariates. Within-group t-tests 
were used to evaluate additional improvement from post-treatment to one-year follow-
up. Between group t-tests were used as post-hoc tests. Within and between-group effect 
sizes were calculated, based on the pooled standard deviation, and expressed as 
Cohen’s d. Weekly treatment gains were evaluated using repeated measurement 
ANOVA. In addition to the analyses on the main trial, data were pooled with those 
from a subsequent RCT including an ICBT and a bibliotherapy arm and re-analysed 
[186]. This was done to increase power to detect potential differences between ICBT 
and bibliotherapy. Analyses were conducted according to the intention-to-treat (ITT) 
principle using last observation carried forward (LOCF) to replace missing data. 
 
3.1.3 Results 
3.1.3.1 Attrition 
Of the 120 participants 1 (1%) was lost to post-assessment and 12 (10%) to follow-up. 
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3.1.3.2 Efficacy of ICBT and bibliotherapy  
Time course of improvement of ICBT, BIB and WLC is shown in Figure 3. 
ANCOVAs for post-treatment change, using baseline values as covariates, revealed 
significant main effects of the group factor (ICBT/BIB/WLC) on all primary (F=11.63-
17.81, df=2,114; p<0.001) and secondary (F=5.09-11.41, df=2,114; p<0.01) outcome 
measures, indicating differential improvement over the treatment period. Bonferroni-
corrected pairwise comparisons showed that both the ICBT and the BIB groups were 
significantly more improved in comparison to the WLC group on all social anxiety 
measures (p<0.001) as well as on the BAI (p≤0.02), MADRS (p≤0.001) and QOLI 
(p≤0.03). The ICBT and BIB groups did not differ significantly on any measure 
(p>0.10). There were no corresponding effects of group, i.e. no differential change, at 
one-year follow-up (F=0.31-2.57, df=2,111, p=0.73-0.08). All pairwise comparisons 
also remained insignificant (p>0.10) at this time. While the ICBT and BIB groups 
improved significantly (p<0.05) from pre-to post-treatment on all measures, additional 
improvement from posttest to follow-up was noted only in the former group on primary 
measures (t=2.58-4.12, df=39, p=0.02-0.001).  
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Figure 3. Time course of improvement on the LSAS-SR 
Abbreviations: ICBT, Internet-based cognitive behaviour therapy; BIB, Bibliotherapy; WLC, Waiting list control; 
LSAS-SR, Liebowitz Social Anxiety Scale-self-report; IY-FU, One-year follow-up 
 
3.1.3.3 Effect sizes 
For social anxiety measures, effect sizes in the ICBT group ranged between 0.85-1.29 
at post-treatment and between 1.10-1.71 at follow-up relative to baseline. The 
corresponding effect size ranges in the BIB group were 0.67-0.89 and 0.72-1.02. Both 
ICBT and BIB were associated with moderate to large effect sizes for changes in the 
BAI and the MADRS-S whereas small to moderate effects were noted for changes in 
QOLI-scores. The pre-post effect size range on measures of social anxiety in the WLC 
group was -0.01-0.05. 
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3.1.3.4 ICBT vs. bibliotherapy: Pooled analyses 
As stated in the methods section, additional analyses were performed pooling data from 
the present trial with data from a subsequent trial adopting largely the same ICBT and 
bibliotherapy in order to increase sample sizes (to n = 69/68), and thus the statistical 
power. In ANCOVAs for post-treatment change on primary measures, relative to 
baseline, the group factor (ICBT/BIB) remained insignificant (F=0.10-0.55, df=1, 134, 
p=0.92-0.44) indicating similar levels of short-term improvement with the two types of 
treatment.  
 
The corresponding analyses of change between baseline and one-year follow-up 
revealed a significant effect of group on the SPS (F=4.14, df=1,134, p<0.05) and 
marginal effects on the SIAS (F=3.54, df=1,134, p=0.062) and LSAS-SR (F=3.89, 
df=1,134, p=0.051). The adjusted means of these measures indicated better long-term 
improvement in the pooled ICBT group. While both treatments were associated with 
significant improvement from pre-to post-treatment, only the pooled ICBT group 
improved significantly from post-assessment to one-year follow-up. This was noted for 
primary measures only (t=2.52-4.20, df=68, p=0.014-0.001). The average within-group 
effect sizes for change on social anxiety measures from baseline to one-year follow-up 
were 1.33 (pooled ICBT) and 0.89 (pooled BIB).  
 
3.1.4 Discussion 
Although the ICBT relied solely on online therapist contact, the treatment proved to be 
efficacious and yielded equivalent effect sizes on measures of social anxiety compared 
to previous RCTs that employed some form of additional guidance [13, 14]. 
Intriguingly, bibliotherapy had significant and reliable effects in persons suffering from 
SAD. Contrary to expectation, the magnitude of improvement did not differ 
significantly between ICBT and bibliotherapy immediately following therapy even 
when pooled data were used. However, only the ICBT group displayed further 
improvement from post-treatment to follow-up, and a significant difference in favour of 
ICBT was noted on the SPS a year after treatment.  
 
The present study suggests that neither the Internet-format nor therapist feedback is 
necessary for obtaining clinical improvement. However, as far from all participants 
achieved remission, the tendency of ICBT to be superior in the long term should be 
taken seriously. A limitation of the study is the lack of clinician assessments which 
meant that all estimates of treatment efficacy relied on self-report. 
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3.2 STUDY II. INTERNET-BASED COGNITIVE BEHAVIOUR THERAPY 
VS. COGNITIVE BEHAVIOURAL GROUP THERAPY FOR SOCIAL 
ANXIETY DISORDER: A RANDOMISED CONTROLLED NON-
INFERIORITY TRIAL 
 
3.2.1 Context and aims 
Although ICBT for SAD has demonstrated effects in line with cognitive behavioural 
group therapy (CBGT), which is the most validated and established treatment [9, 10, 
38, 143], the current evidence holds a number of limitations [13, 14, 186, 209, 211, 
216]. There has been no comparison to conventional CBT, such as CBGT, and most 
studies have relied solely on self-report instruments as measures of treatment outcome. 
In addition, most studies have been conducted in university settings, which might have 
a different impact on treatment experience and outcome compared to receiving care at a 
psychiatric clinic. Finally, diagnostic procedures may be more clinically valid when 
conducted in a clinical setting.  
 
In summary, more empirical evidence is needed before ICBT can be validly employed 
in a psychiatric context. As CBGT is an effective gold standard treatment appropriate 
for use as a benchmark, the necessary evidence to validate ICBT is to demonstrate non-
inferiority (i.e., at least equal effectiveness) to CBGT [225]. The aim of the present 
study was to compare the effects of ICBT and CBGT for patients with SAD when 
administered in a psychiatric setting. We hypothesised that ICBT would be at least as 
effective as CBGT in reducing social anxiety. We also predicted that the two treatments 
would be equal on secondary outcome measures of depressive symptoms, general 
anxiety, quality of life, and global functioning. 
 
3.2.2 Methods 
3.2.2.1 Trial design 
This was a non-inferiority trial within the context of a parallel group study with 
unrestricted randomisation in 1:1 ratio. The trial was conducted at a psychiatric 
outpatient clinic and outcome assessors were blind to treatment status. 
 
3.2.2.2 Recruitment and selection 
Participants were recruited to the clinic by referral from primary care physicians and 
psychiatrists, and by self-referral. The main inclusion criteria were largely the same as 
in Study I. Potential participants were invited to attend an interview with a psychiatrist 
to confirm the SAD diagnosis and to establish whether they met the remaining 
inclusion criteria. Of the 230 applicants, 126 met all inclusion criteria and were 
randomised to ICBT (n=64) or CBGT (n=62). Of the included, 45 (36%) were women 
and the mean age was 35.4 years (SD=11.4) 
 
3.2.2.3 Outcome measures and assessments 
The primary outcome measure was the clinician administered Liebowitz Social Anxiety 
Scale [LSAS; 226]. The other continuous outcome measures were the same as in Study 
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I, except that the SPSQ was dropped and that the Anxiety Sensitivity Index [ASI; 227] 
was added. Axis-I-disorders were established using the SCID-I-RV and the Mini 
International Neuropsychiatric Interview [MINI; 228]. A treatment credibility scale 
comprising five items was administered to determine whether participants viewed the 
two treatments as equally credible [229]. Prior to randomization participants were 
asked to state their treatment preference (ICBT or CBGT). Assessments, including 
diagnostic interviews, were conducted before treatment, immediately after treatment, 
and six months after treatment. During treatment, the LSAS-SR was administered on a 
weekly basis. To ensure the integrity of the blinding procedure, participants were 
instructed not to mention which treatment they had received during the post-treatment 
and follow-up interviews. After completing the interviews, the assessing psychiatrists 
guessed allocation status for each participant. 
  
3.2.2.4 Monitoring of treatment integrity 
Treatment integrity of CBGT was ensured in three ways. First, a detailed treatment 
manual was used [22]. Second, group therapists received supervision throughout the 
trial by a licensed psychotherapist specialised in CBT for SAD. Third, all sessions were 
audio recorded and a random sample of 5 sessions was audited by a clinical 
psychologist with more than 10 years of experience in treating SAD with CBT. Using 
the Therapist Adherence Scale (TAS) developed by the originators of CBGT [230], all 
reviewed sessions were judged to have been conducted in accordance with the 
treatment manual.  
  
3.2.2.5 Treatments 
3.2.2.5.1 Internet-based cognitive behavior therapy  
The ICBT employed in this study was the same as in Study I, with the only main 
difference being that the treatment duration was extended to15 weeks.  
 
3.2.2.5.2 Cognitive behavioural group therapy  
 This treatment comprised an initial individual session followed by 14 group sessions 
over 15 weeks. The CBGT followed the protocol developed by Heimberg and Becker 
[22] as outlined in the Introduction section of the thesis.  
 
3.2.2.6 Statistical analysis 
The non-inferiority margin of the primary outcome measure LSAS was set at ∆10 
points, which was based on clinical judgment and a review of the evidence of CBGT 
compared to credible control conditions for SAD. Meta-analytic reviews have 
estimated the lower bound of the 95% confidence interval (CI) of the between group 
effect size to 0.39 (Hedges’g) [231]. Assuming a standard variance of LSAS scores in 
our sample, this supported the use of 10 LSAS points as a non-inferiority margin. Test 
criterion for non-inferiority was that the lower bound of the 95% CI of the mean 
difference should fall within ∆. With 95% probability, the mean difference between 
ICBT and CBGT had to be smaller than 10 LSAS points. For the other continuous 
measures, the non-inferiority margin was set at ∆ Cohen’s d=0.5. Test criterion for non-
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inferiority for these measures was that the lower bound of the 95% CI of between group 
effect sizes should fall within this range.  
 
Main outcome continuous variables were analysed using a linear mixed effects model 
employing the restricted maximum likelihood method assuming a compound symmetry 
model as covariance structure [232]. To assess clinical significant improvement we 
used the criteria proposed by Jacobson and Truax [233]. The remaining analyses were 
carried out in the same fashion as in Study I. The sample size was considered 
satisfactory since power calculations showed that there was a chance slightly lower 
than 80% to detect a difference, given the non-inferiority criteria used and an alpha-
level of .05. The main analyses were conducted in accordance with the ITT-principle. 
 
3.2.3 Results 
3.2.3.1 Attrition 
At post-assessment, 63 of 64 (98%) participants in the ICBT group completed the self-
report questionnaires and 59 (92%) participants attended the clinical assessment 
interview. The corresponding numbers in the CBGT group were 62 of 62 (100%) and 
52 (81%).  
 
3.2.3.2 Non-inferiority and effect sizes 
At post-treatment and six month follow-up respectively, the 95% CI of the mean 
difference between the groups on LSAS was 0.68-17.66 and -2.5-15.69, favouring 
ICBT. This was well within the non-inferiority margin of 10 LSAS points for the lower 
bound. Analysis of the other continuous measures showed that all lower bounds of 95% 
CIs for between group effect sizes fell well within the non-inferiority margin of d=0.5. 
At post-assessment and follow-up, the between-group effect size range of social anxiety 
measures was 0.04-0.41, favouring ICBT.  
 
3.2.3.3 Treatment effectiveness - primary outcome measure (LSAS) 
At post-treatment, 35 (55%) of the participants (95% CI, 43%-67%) in the ICBT group 
were classified as responders compared to 21 participants (34%) in the CBGT group 
(95% CI, 22%-46%). At six-month follow-up, the corresponding number was 41 (64%) 
in the ICBT group (95% CI, 52%-76%) and 28 (45%) in the CBGT group (95% CI, 
33%-58%). Mixed effects model analysis showed a significant effect of time, indicating 
improvement in both treatment groups (F=179.06; df=1,219; p<.001). There was no 
significant interaction of group and time for the primary outcome measure LSAS, 
indicating similar improvement across groups (F=1.58; df=2, 219; p=.21). As 
illustrated in Figure 4, there were continuous within group improvements throughout 
the trial on the LSAS-SR in both conditions.  
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Figure 4. Weekly symptom change on the LSAS-SR 
Abbreviations: ICBT, Internet-based Cognitive Behaviour Therapy; CBGT, Cognitive Behavioural Group 
Therapy; Pre, before treatment;  Post, post-treatment; 6MFU, six months after treatment;  CA, Clinician assess-
ment; LSAS-SR, Liebowitz Social Anxiety Scale-self-report version. Note: Error bars represent 95 % CIs.   
 
 
3.2.3.4 Treatment effectiveness - secondary outcome measures 
3.2.3.4.1 Social anxiety 
There was a significant effect of time on the SIAS and SPS (F=80.95 -83.39; df=2, 
p<.001). Mixed effects model analysis showed no significant interaction of group and 
time for these variables (F=0.30-0.48; df=2, 244; p=.62-.74). 
 
3.2.3.4.2 Depression, general anxiety, anxiety sensitivity and quality of life 
There was a significant effect of time on MADRS-S, BAI, ASI and QOLI (F=17.26-
52.30; df=2, 227-245; p<.001). Analysis using mixed effects model yielded no 
significant interaction of group and time for these variables (F=0.26-1.30; df=2, 227-
245; p=.28-.77).  
 
3.2.3.4.3 Psychiatric diagnosis at each assessment point 
Following treatment, 18 (31%) participants who had received ICBT no longer met 
diagnostic criteria for SAD (28% if considering dropouts as non-responders). The 
corresponding number for participants who underwent CBGT was 12 (23%; 19% if 
considering dropouts non-responders). At follow-up, 25 (46%) participants who had 
received ICBT (41% if considering dropouts non-responders) and 21 (40%) receiving 
CBGT (34% if considering dropouts non-responders) no longer met diagnostic criteria 
for SAD. At post-treatment and six month follow-up there was no significant difference 
in the prevalence of SAD between groups (χ2=037-1.33, df=1, p=.25-.55). 
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3.2.3.4.4 Treatment credibility, blinding, adherence and treatment preference 
Analysis of credibility ratings after one week of treatment showed that there was no 
significant difference in treatment credibility between treatment groups (t (1, 110)=0.07, 
p=.95). 
 
In four instances the blinding was broken. On two occasions participants accidentally 
mentioned their treatment allocation status to the assessor, and in other two occasions it 
was deemed necessary to break the blinding because of the need to assess increased 
depressive symptoms during treatment. There was no significant association between 
assessors’ guess and actual treatment allocation (χ2=0.27, df=1, p=.61), indicating 
successful blinding.  
 
Prior to randomization participants were asked to state their treatment preference. Of 
126 participants, 68 (54%) preferred ICBT and 58 (46%) CBGT. There was no 
difference between groups in terms of proportion of participants that received the 
preferred treatment (χ2=0.77, df=1, p=.38).  
 
In CBGT, the average number of attended sessions per participant was 9.40 (SD=4.87) 
out of a possible total of 15. Fifty participants in CBGT (81%) attended at least five 
sessions and 17 (27%) attended all sessions. The average number of completed 
modules in ICBT was 9.33 (SD=4.95) of 15. Fifty-one participants in ICBT (80%) 
completed at least 5 modules and 19 (29.7%) completed all modules.  
 
3.2.3.4.5 Evaluation of therapist resources required for each treatment 
On average, therapists delivering ICBT spent 5.5 minutes (SD=3.6) weekly per patient. 
The corresponding amount of time in CBGT was 50 minutes (2.5 h sessions with two 
therapists and 6 patients).  
 
3.2.4 Discussion 
The present study is the first study to demonstrate that ICBT can be as effective as 
CBGT in the treatment of SAD. The CIs of mean differences of the primary outcome 
measure fell well within the non-inferiority margin and between-group effect sizes 
were small but consistently favoring ICBT on the social anxiety measures. There was 
also a large proportion of participants who were classified as much improved or very 
much improved at post-treatment and follow-up in both treatment groups. The follow-
up assessment indicated that treatment gains were sustained on all measures.  
 
In trials assessing non-inferiority it is essential that the effect of the gold standard 
treatment is as effective as in previous trials. This was the case in the present study, 
where CBGT yielded effects in line with trials conducted by its originators [133]. 
Moreover, treatment effects for ICBT were equivalent to those reported in previous 
controlled trials [13, 14, 209, 211, 216]. As reduced therapist time is an important 
element of ICBT, a key finding in this study is that ICBT reduced therapist time per 
treated patient by 90% compared to CBGT. As outlined in the introduction of the thesis 
individual CBT may be even more effective than CBGT. However, as CBGT has been 
evaluated in more trials and is more established, we decided to use CBGT as the 
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benchmark treatment. Also, in a recent study by Andrews and colleagues, individual 
CBT did not show superiority over ICBT, albeit power was somewhat more limited 
compared to the present study [207].  
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3.3 STUDY III. FIVE-YEAR FOLLOW-UP OF INTERNET-BASED 
COGNITIVE BEHAVIOUR THERAPY FOR SOCIAL ANXIETY 
DISORDER 
 
3.3.1 Context and aims 
While several studies have shown that conventional CBT for SAD produces long-term 
improvements up to five years after treatment [234-237], nearly all studies on ICBT 
have had a follow-up period of one year or shorter. The one exception is a study where 
participants receiving ICBT not only maintained their treatment gains but were further 
improved at a 2.5-year follow-up [238]. This is in line with the notion that reduced 
anxiety following CBT to a large extent is contingent on repeated exposure [239]. The 
aim of the present study was to investigate the effects of ICBT for SAD five years after 
treatment. No previous study has investigated if the effect of ICBT persists over this 
long period of time. We hypothesised that treatment gains would be sustained on 
measures of social anxiety, depressive symptoms, general anxiety and quality of life. 
 
3.3.2 Methods 
3.3.2.1 Design 
This was a follow-up study assessing 80 participants who had received ICBT for SAD 
within the context of an RCT (Study I). In the original RCT, participants were 
randomised to ICBT (n=40) WLC (n=40) with equal probability (the bibliotherapy arm 
was not included in this study). Following treatment and post-assessment, participants 
in the WLC group were crossed over to treatment and the group is henceforth denoted 
WL-ICBT. Thus, both groups had received ICBT at one-year follow-up. As the ICBT 
and WL-ICBT groups received treatment at different time points, results are reported 
separately for the two groups. 
 
3.3.2.2 Recruitment and treatment 
See Study I. 
 
3.3.2.3 Outcome measures 
The primary outcome measure was the LSAS-SR [221]. We also used  the SIAS [222],  
and the SPS [222] as complementary measures of social anxiety. In addition, the 
MADRS-S [219], the BAI [223]  and the QOLI [224]  were used as secondary 
measures to assess depressive symptoms, general anxiety, and quality of life,  
respectively. 
  
3.3.2.4 Clinical assessment interview 
The SCID-I-RV  [220] was used to establish whether participants met diagnostic 
criteria for SAD at five-year follow-up. Global improvement was measured by the 
Clinical Global Impression Improvement Scale  [CGI-I; 240]. In addition, information 
about current and earlier psychological and pharmacological treatments was obtained. 
Finally, participants were asked to rate to which extent they attributed their 
improvement/current state to ICBT. 
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3.3.2.5 Procedure 
The clinical assessment interview was performed by a clinical psychologist with more 
than five years of experience in working with structured diagnostic assessments. The 
interview was conducted by telephone, which has been shown to be a reliable way of 
assessing psychiatric symptoms [241, 242].  
 
3.3.2.6 Statistical analysis 
While data were analysed on ITT basis, last observation carried forward to handle 
missing data was not applied as that might have exaggerated the degree to which gains 
were sustained. Instead, estimated parameters were obtained using a mixed-models 
approach. [232]. The following formula was used for converting standard errors to 
standard deviations: SD=SE(√n). As all participants received ICBT, the main analyses 
entailed no between group comparisons. Nominal data were analyzed with McNemar’s 
test of change.  
 
3.3.3 Results 
3.3.3.1 Attrition 
Of 80 participants, 71 (89%) attended the clinical assessment interview and 64 (80%) 
completed the LSAS-SR, SIAS, SPS, MADRS-S, BAI and QOLI. There were no 
statistical significant differences between participants who did not provide follow-up 
data and those who did regarding gender (χ2=0.39, df=1, p<.39), age, and social anxiety 
at baseline or at one-year follow-up (t (1, 67-78)=0.40-1.74, p<.68-.09).  
 
3.3.3.2 Social anxiety measures 
Figure 5 displays changes on the primary outcome measure LSAS-SR across 
assessment points. The effect sizes at five-year follow-up in comparison to baseline 
were large on the LSAS-SR, d=1.3 (95% CI 0.8-1.8) in the ICBT group and d=1.4 
(95% CI 0.9-1.9) in the WL-ICBT group. Mixed effect models analysis showed a 
significant effect of time on the primary outcome measure LSAS-SR, as well as on the 
SIAS and SPS (F=16.05-29.20; df=3, 98-102; p<.001).  
 
Pairwise comparisons showed that participants in both groups were significantly 
improved from baseline to one- and five-year follow-up on all social anxiety measures 
(F=15.10-90.05; df=1, 33-38; p<.001). Both groups were further improved at one-year 
follow-up compared to post-assessment (F=7.43-40.42; df=1, 34-35; p<.01-.001). 
There were no significant changes on the LSAS and SPS between one- and five-year 
follow-up (F=0.22, 0.93; df=1, 28, 32; p<.64-.13). In the WL-ICBT group, but not in 
the ICBT group, participants were further improved on the SIAS at five-year follow-up 
compared to one-year follow-up (F=7.85; df=1, 29; p<.01).  
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Figure 5. Improvement course on the primary outcome measure LSAS-SR during 
the follow-up period. 
 
Abbreviations: ICBT, Internet-based Cognitive Behaviour Therapy; WL-ICBT, Waiting list followed by 
Internet-based Cognitive Behaviour Therapy; Pre, before treatment;  Post, post-treatment; 1Y-FU, one year after 
treatment; 5Y-FU, five years after treatment; LSAS-SR, Liebowitz Social Anxiety Scale-Self-Report. 
 
 
3.3.3.3 Depressive symptoms, general anxiety and quality of life 
Mixed effect models analysis showed a significant effect of time on the MADRS-S, 
BAI and QOLI (F=4.64-9.78; df=3, 97-104; p<.01-.001). Pairwise comparisons 
showed that participants in both groups were significantly improved from baseline to 
one- and five-year follow-up on MADRS-S, BAI and QOLI (F=4.7-30; df=1, 32-40; 
p<.04-.001). The WL-ICBT was further improved at one-year follow-up compared to 
post-assessment on these measures (F=12.12-13.83; df=1, 34, 35; p<.001), whereas the 
ICBT group was not (F=0.36-3.09; df=1,35-37; p<.55-.09). There were no changes on 
these measures from one-to five-year follow-up (F=0.01-3.80; df=1, 28, 33; p<.94-.06).  
 
3.3.3.4 Clinical assessment interview 
3.3.3.4.1 Global improvement and diagnostic assessment 
At five-year follow-up, 24 participants (60%) in the ICBT group and 27 (67.5%) in the 
WL-ICBT group were considered very much or much improved, i.e. responders. At 
five-year follow-up, 19 participants (48%) in both groups no longer met diagnostic 
criteria for SAD according to the clinician assessment (counting dropouts as non-
responders). McNemar’s test showed that this was a statistically significant change 
compared to baseline (p<.001). 
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3.3.3.4.2 Participants’ attribution of improvement 
Participants were asked to rate to which extent they attributed their improvement to the 
ICBT on a Likert-scale from 0-100 (0=any improvement is completely unrelated to 
ICBT; 50=any improvement is equally due to ICBT and other causes; 100=any 
improvement is completely due to ICBT). In the ICBT group, the average score was 
60.3 (SD=26.9) and the corresponding WL-ICBT score was 61.8 (SD=25.9). 
 
3.3.3.4.3 Other psychological and psychotropic treatments received since ICBT 
At five-year follow-up, four (10%) participants in the ICBT group had received some 
form of psychological treatment (all reasons included) after ICBT. The corresponding 
number in the WL-ICBT group was seven (17.5%). One participant (2.5%) in the ICBT 
group was taking psychotropic medication (SSRI) at the time of the five-year follow-up 
assessment, although four participants (10%) had started and discontinued psychotropic 
medication at some point during the follow-up period (all SSRIs). In the WL-ICBT 
group, the corresponding numbers was 3 (7.5%) and 5 (12.5%), respectively (all 
SSRIs). 
 
3.3.4 Discussion 
The aim of this study was to evaluate the five-year effect of ICBT for SAD by 
assessing participants receiving treatment in Study I. The results showed that 
improvements on measures of social anxiety at one-year follow-up were sustained five 
years after treatment. Overall, effect sizes were large on measures of social anxiety. 
Improvements regarding depressive symptoms, general anxiety and quality of life were 
also sustained at five-year follow-up. The results of this study indicate that participants 
receiving ICBT for SAD are moderately improved immediately following treatment, 
but make further improvements within the following year. Improvements made at one-
year follow-up are, in turn, long-term enduring. 
 
The effect sizes in this study are in line with those reported in studies investigating the 
long-term effects of conventional CBT for SAD [235, 243]. The major strength of this 
study is that attrition rates were low making the generalizability of the findings high. 
Furthermore, participants attributed their improvement to ICBT to a large extent and 
few had commenced other forms of psychological or psychotropic treatments after 
completing ICBT. Taken together, this suggests that the reduction of social anxiety 
observed at five-year follow-up was largely an effect of ICBT.  
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3.4 STUDY IV. COST-EFFECTIVENESS AND COST-UTILITY OF 
INTERNET-BASED COGNITIVE BEHAVIOUR THERAPY VS. COG-
NITIVE BEHAVIOURAL GROUP THERAPY FOR SOCIAL ANXIETY 
DISORDER: RESULTS FROM A RANDOMISED CONTROLLED TRIAL 
 
3.4.1 Context and aims 
Several features of SAD contribute to making it an economic burden from a societal 
perspective. It is highly prevalent [8], has an onset in early adolescence [6], and is 
associated with academic underachievement and an increased risk of unemployment [3, 
4]. As ICBT requires a limited amount of therapist resources, often less than 10 minutes 
weekly per patient [12, 203], it has the potential of being a more cost-effective 
treatment than conventional CBT. To date, no study has prospectively investigated the 
economic impact and cost-effectiveness of ICBT or CBGT for SAD from a societal 
perspective. The aim of the present study was to investigate the economic impact of 
ICBT compared to CBGT for SAD from a societal perspective within the context of an 
RCT. We hypothesised that the treatments would generate significant and equivalent 
societal cost reductions. In addition, we expected ICBT to be more cost-effective due to 
lower costs of treatment. 
 
3.4.2 Methods 
3.4.2.1 Trial design 
This was a prospective cost-effectiveness analysis study adopting a societal 
perspective. The data were collected from the participants receiving ICBT (n=64) or 
CBGT (n=62) in the RCT of Study II. 
 
3.4.2.2 Assessment of costs 
Health economic cost data were obtained using the Trimbos and Institute of Medical 
Technology Assessment Cost Questionnaire for Psychiatry [TIC-P; 244]. The human 
capital approach was used which means that monetary losses associated with work loss 
and work cutback were based on the average gross earning in Sweden for the duration 
of the sick leave [245]. The direct medical costs associated with ICBT and CBGT were 
mainly represented by the costs of therapists. In this study, the tariff of visits to licensed 
clinical psychologists was used when estimating costs for both treatments. The time the 
therapists spent on treating the participants were registered and multiplied with this 
tariff.  
 
3.4.2.3 Clinical assessments and treatments 
The primary outcome measure was the LSAS [LSAS; 226, 246]. The procedure and 
other assessment instruments used are described in Study II. We used the EuroQol 
[EQ-5D; 247] to assess quality of life from a health perspective. Treatment 
interventions were ICBT and CBGT as presented in Study II. 
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3.4.2.4 Statistical analysis 
Analyses were conducted in accordance with the ITT-principle using LOCF. Costs 
were assessed at pre-treatment, post-treatment and six month follow-up. All costs were 
extrapolated to a six month period. Since the cost data were non-normally distributed, 
p-values were estimated using a general linear model with bootstrap analysis (5,000 
replications) [248]. Incremental cost effectiveness ratios (ICERs) were estimated using 
the following formula:  
∆C1 – ∆C2 
∆E1 – ∆E2 
In the formula, C1–C2 is the difference in costs between ICBT and CBGT conditions 
and E1–E2 refers to difference of the average effectiveness of the two conditions [245]. 
The costs, including all medical and non-medical costs, of the participants in the ICBT 
condition were subtracted from the costs of the participants in the CBGT condition. 
This difference was then divided with the subtracted effects (in this case improvement 
of social anxiety assessed with the LSAS). This procedure was bootstrapped 5,000 
times, generating an estimated figure of the treatment groups’ incremental costs in 
relation to their incremental health benefit. A cost-utility analysis was also conducted, 
i.e. an analysis identical to cost-effectiveness analysis with the exception that the cost 
of an additional quality adjusted life year [QALY; 199] is calculated. Finally, data 
robustness was tested in sensitivity analyses. This was done by repeating the analysis 
while increasing the estimated intervention cost of ICBT. First, $200 was added 
corresponding to a scenario of reduced production capacity of ICBT due to poorer 
treatment planning rendering longer average time spent in the system [249]. Second, 
$600 was added to the cost of ICBT corresponding to the cost of ICBT during the first 
year of providing the service, thereby including all developmental costs and costs of 
establishing the treatment unit.  
 
3.4.3 Results 
3.4.3.1 Costs 
Participants in both treatments significantly reduced their gross total costs at six-month 
follow-up in comparison to pre-treatment (t (61-63)=2.00-2.38, p<.02-05). During this 
period the gross total cost reduction was $1885 in the ICBT group and $2810 in the 
CBGT group. The indirect non-medical costs were also reduced in both groups at 
follow-up, (t (61-63)=2.21-2.45, p<.02-03). There were however no significant reductions 
of gross total costs at post-treatment compared to pre-treatment (t (61-63)= 1.89-1,11), 
p<.07-.28)  There were no significant between group differences in any of the cost 
domains at post-treatment or follow-up (t (1, 124)=0.13-0.16, p<.16-90). The intervention 
costs per participant were estimated to $464 (SD=128) for ICBT and $2687 (SD=0) for 
CBGT (t=137, df=1,124, p<0.001). The difference in costs of ICBT and CBGT was 
attributable to the differences in therapist time required. On average, therapists 
delivering ICBT spent 5.5 minutes (SD=3.6) weekly per patient. The corresponding 
amount of time in CBGT was 50 minutes (2.5 h sessions with two therapists and 6 
patients). Taking nonattendance into consideration, this number would have been even 
higher in the CBGT condition. 
 50 
3.4.3.2 Cost-effectiveness  
At follow-up, the incremental cost effectiveness ratio (ICER) was -1335/ 0.19 = -7046 
favouring ICBT over CBGT. This means that that each incremental clinical significant 
improvement on LSAS for participants in ICBT relative to CBGT generated a societal 
earning of $7046. This was because the total net costs were lower in the ICBT 
condition compared to the CBGT condition and that clinical significant improvements 
in social anxiety were slightly more likely to occur in the ICBT condition. Figure 6 
presents the scatter of simulated ICERs across the four quadrants of the ICER plane. A 
majority of the simulated ICERs are located in the south east quadrant (79.5%) 
compared to 19.0% in the north east quadrant, indicating that ICBT is cost-effective 
compared to CBGT.  The same data are used to plot the acceptability curve in Figure 7, 
which also displays the two sensitivity analyses curves. The curve indicates that ICBT 
has an 81% probability of being cost-effective if society were willing to pay $0 for one 
additional improved patient with SAD. If society were willing to pay $3000 for one 
case of improvement, the probability of ICBT being cost-effective would increase to 
89%.  
 
 
 
 
Figure 6. Cost-effectiveness plane comprising 5000 boot strapped ICERs 
comparing ICBT to CBGT. 
Abbreviations: ICBT, Internet-based cognitive behaviour therapy; CBGT, cognitive behavioural 
group therapy. 
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Figure 7. Cost-effectiveness acceptability curve for ICBT compared to CBGT. 
Note: Solid line (main analysis) represents probability of ICBT being cost-effective under regular 
circumstances; Sensitivity analyses 1 represents the acceptability curve if $200 (low productivity scenario) is 
added to the cost of ICBT and Sensitivity analysis 2 if $600 is added (first year of implementation). 
Abbreviations: ICBT, Internet-based cognitive behavior therapy; CBGT, cognitive behavioural group therapy. 
 
3.4.3.2.1 Cost-utility analysis 
Participants in both treatment conditions reported higher quality of life at post-
treatment (t (61-63)=3.88-2.16, p<.001-.03) and six-month follow-up (t (61-63)=3.14-3.46, 
p< .001-.01) compared to pre-treatment according to the EQ-5D. At follow-up, the 
cost-utility ICER was -1335 / 0.075 = -17 823. This meant that one additional QALY 
generated a societal earning of $17 823 when comparing ICBT to CBGT. The 
bootstrapped ICER data indicated that ICBT has an 81% probability of being cost-
effective if society would pay $0 for one gained QALY. If society were willing to pay 
$40,000 for one additional QALY, the probability of ICBT being cost-effective would 
remain about the same (79%). 
 
3.4.3.2.2 Sensitivity analyses 
As shown in Figure 7, ICBT would remain the most cost-effective treatment even if 
increasing the cost of ICBT corresponding to a) a scenario of low productivity or b) the 
costs of treatment in the first year of implementation.  
 
3.4.4 Discussion 
As expected, both treatments generated a substantial reduction of societal costs. The 
hypothesis that ICBT would be a cost-effective treatment alternative in comparison to 
CBGT, was also supported. This was a result of equivalent effects of the treatments in 
terms of reducing societal costs, social anxiety and improving quality of life, but 
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significantly lower intervention costs for ICBT compared to CBGT. This difference 
was primarily due to less therapist time required in ICBT. The sensitivity tests showed 
that the findings were robust in the sense that ICBT would be the most cost-effective 
treatment even if using conservative intervention cost estimates. Although ICBT was 
more cost-effective than CBGT it is important to note that both treatments generated 
large cost reductions and considering the chronicity of SAD [7, 250], it is highly likely 
that both treatments generate societal cost savings compared to no treatment. These 
results are interesting from a health care policy perspective as they show that the 
savings generated exceed the cost of treatment in a remarkably short time frame. This 
implies that society as a whole would be financially strengthened by making CBT for 
SAD more accessible.  
 
A limitation of the study was that the estimates of costs were based on TIC-P, which is 
a self-report questionnaire and thereby potentially less accurate compared to data 
collected directly from public registers. This risk, however, is likely to be equal across 
treatments, making it unlikely that it could account for between group differences and 
empirical evidence suggests that economic data obtained by self-report is equally valid 
compared to register collected data [251]. In spite of this limitation, the results of the 
present study are important as they show that CBT for SAD in general and ICBT in 
particular, generate substantial societal cost reductions. 
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3.5 STUDY V. CLINICAL AND GENETIC OUTCOME DETERMINANTS  
OF INTERNET- AND GROUP-BASED COGNITIVE BEHAVIOUR 
THERAPY FOR SOCIAL ANXIETY DISORDER 
 
3.5.1 Context and aims 
A substantial proportion (25-50%) of those receiving ICBT and cognitive behavioural 
group therapy (CBGT) do not respond sufficiently well to treatment [133, 186]. Under 
these circumstances, the identification of outcome predictors and moderators could 
facilitate: a) reduced dropout rates and number of treatment failures [161, 162], and b) 
individually tailored treatments [161, 163].  
 
The general aim of the present study was to investigate demographic, clinical, therapy 
processes related and genetic predictors and moderators of treatment outcome of ICBT 
compared to CBGT. Specific aims were to investigate predictors and moderators of a) 
the main continuous outcome measure of social anxiety, and b) fulfilment of diagnostic 
criteria for SAD. Finally, we aimed to identify subgroups likely to achieve clinical 
significant improvement by producing a clinical decision tree entailing optimal 
predictor and sub predictor cut-off points.  We expected that variables indicating strong 
social support, less psychiatric comorbidity, treatment adherence and receiving the 
preferred type of CBT would predict treatment response. In addition, we hypothesised 
that non S-allelic carriers of the serotonin transporter gene promoter (5-HTTLPR) 
polymorphism, and non-met allelic carriers of the catechol-O-methyltransferase gene 
polymorphism (COMTvalmet158) and the brain derived neurotrophic factor 
(BDNFval66met) gene polymorphism would have a superior treatment response. 
 
3.5.2 Method 
3.5.2.1 Trial design, recruitment and treatment interventions 
This was a study assessing predictors and moderators within the context of a parallel 
group trial with unrestricted randomisation in 1:1 ratio (Study II of the thesis). 
Participants were 126 persons with SAD who participated in Study II. See Methods in 
Study II for inclusion criteria and recruitment. The treatments were ICBT and CBGT. 
 
3.5.2.2  Main dependent variables 
The primary outcome measure was the clinician administered LSAS [246]. Clinical 
significant improvement was based on the LSAS using the criteria proposed by 
Jacobson & Truax [233]. The SCID-I-RV was used to establish SAD diagnosis.  
 
3.5.2.3 Potential predictors and moderators 
3.5.2.3.1 Demographic characteristics and personality traits 
Demographic data were collected in the diagnostic interviews. To assess personality 
traits, we used the Swedish Scales of Personality [SSP; 252]. 
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3.5.2.3.2 Clinical characteristics and therapy process related measures 
In the diagnostic interviews, we used the SCID-II [253] to assess avoidant personality 
disorder and MINI to assess axis I disorders other than SAD. Data regarding age of 
onset and severity of social anxiety were also collected in these interviews. Continuous 
assessment of depressive symptoms and general anxiety was conducted using the 
MADRS-S and the BAI respectively.  
 
The Credibility scale was administered to determine whether participants viewed the 
respective treatment as credible and likely to be effective. Prior to randomisation 
participants were asked to state their treatment preference (ICBT or CBGT). Whether 
participants received their preferred treatment or not was used as a potential 
predictor/moderator. Treatment adherence was defined as attending at least five group 
sessions (CBGT) or completing at least five modules (ICBT).  
 
3.5.2.3.3 Genetic analysis 
DNA extraction from whole blood was performed using standard methods [254]. For 
the biallelic 5-HTTLPR, two fragments, 336b (short) and 379 bp (long), were amplified 
by polymerase chain reaction (PCR), amplified on Biorade Tetrade (BIORAD, 
Hercules, CA, USA). To genotype COMTval158met (rs4680) and the BDNFval66met 
(rs6265), we used the Taqman® allelic discrimination assay (5' nuclease assay, 
performed on an ABI HT7900 (Applied Biosystems, Foster City, CA)). All genotypes 
were determined in duplicates 
 
3.5.2.4 Statistical analysis 
Three types of data analyses were performed, each corresponding to a specific aim. We 
used two types of regression analyses. In these analyses, the two-step approach 
proposed by de Graaf and co-workers was adopted [167]. This meant identifying 
significant univariate predictors, and subsequently adding those into a final multivariate 
model. Social anxiety measured by the LSAS was analysed within a linear regression 
framework. For each variable a regression model was built using LSAS scores as 
dependent variable and forced entry as regression method. Each model contained LSAS 
baseline values, the potential predictor variable, treatment condition (ICBT/CBGT), 
and the interaction term of predictor and treatment condition. Prior to analyis data were 
standardised and mean centered. All dependent variables were assessed at six-month 
follow-up. As suggested by Holmbeck, a variable is a predictor if it has a main effect 
on the dependent variable and a moderator if there is a significant interaction effect, i.e. 
predictor * treatment condition [255].  
 
The second type of analysis performed was logistic regression using diagnosis of SAD 
as dependent variable applying the same model building approach. Finally, signal 
detection analysis based on recursive partitioning was performed yielding receiver 
operator characteristics (ROC) of subgroups with high and low chance of achieving 
clinical significant improvement [256, 257]. Signal detection is an iterative process of 
splitting the sample in two groups based on the optimal predictor cut-offs. For each 
node in the tree, odds ratios were calculated. Missing LSAS data was handled by 
substituting the clinician score with the LSAS-SR score. Participants not attending the 
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diagnostic interviews were considered having SAD, except if they scored <15 on the 
LSAS-SR, which ensured very high negative predictive value [258]. 
 
3.5.3 Results 
3.5.3.1 Predictors and moderators of social anxiety assessed by the LSAS  
Parameter estimates of significant predictors and moderators of the final linear 
regression analysis are presented in Table 4. 
 
3.5.3.1.1 Demographic variables and personality 
The initial linear regression analyses showed that employment status, educational level, 
having children, and quality of life (QOLI) were significant predictors (i.e., working 
full time, having attended college, having children and a higher QOLI score predicted 
better outcome). The personality traits adventure seeking and impulsiveness were 
significant moderators, meaning that high levels of these traits were associated with less 
social anxiety in CBGT but not in ICBT. In the final model, the predictors employment 
status and having children remained significant.   
 
3.5.3.1.2 Clinical characteristics 
Level of depressive symptoms (MADRS-S) was found to be a significant predictor in 
the initial analysis (i.e. less depressive symptoms predicted better outcome). Comorbid 
depression and general anxiety measured by the BAI were significant moderators, 
showing that absence of depression and lower general anxiety was associated with 
lower LSAS scores in ICBT but not in CBGT. Type of SAD (generalised or not) did 
not moderate outcome. The final model retained depressive symptoms as a predictor 
and general anxiety as a moderator. 
 
3.5.3.1.3 Process related measures 
Treatment credibility and treatment adherence were significant predictors (i.e. higher 
credibility scores and completing at least five sessions or modules predicted better 
outcome). Computer skills did not moderate treatment effects. Both predictors 
remained significant in the final model. 
 
3.5.3.1.4 Genetic factors 
No genetic polymorphisms were significant predictors or moderators. Thus, no genetic 
data were included in the final model.  
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Table 4. Linear regression presenting the final model using LSAS scores at  
six-month follow-up as dependent variable. 
 
           
Variable           
 B  
 
 SE  
  
β  
  
P-value    
Model           
R=.74   17.12    <.001    
R
2
=.54           
Adj R
2
=.52           
           
Predictors           
Employment status 
(working full time) -5.30  1.68  -.22  <.01    
Having children -6.56  3.17  -.13  <.05    
Treatment 
adherence (Yes) -14.20  4.05  -.23  <.001    
Depressive 
symptoms 
(MADRS-S) 2.96  1.70  .12  <.09    
Treatment 
Credibility           
(C-Scale) -6.07  1.68  -.25  <.001    
LSAS baseline 10.01  1.65  .41  <.001    
           
Moderators           
General Anxiety 
(BAI) 5.64  1.59  .23  <.001    
           
Abbreviations: QOLI, Quality of life inventory; MADRS-S, Montgomery Åsberg Depression Rating Scale- 
Self report; C-Scale, Credibility Scale; LSAS, Liebowitz Social Anxiety Scale; BAI, Beck Anxiety Inventory 
 
3.5.3.2 Predictors and moderators of diagnostic status (having SAD or not) 
Table 5 presents parameter estimates of significant predictors found in the final logistic 
regression analysis. 
  
3.5.3.2.1 Demographic variables and personality 
The initial logistic regression analyses showed that having children, higher age and 
lower stress susceptibility predicted better outcome. The personality trait impulsiveness 
was a significant moderator, meaning that a higher level of impulsiveness was 
associated with absence of SAD diagnosis in CBGT but not in ICBT. In the final model 
age remained a significant predictor.  
  
3.5.3.2.2 Clinical characteristics 
Number of years with SAD, depressive symptoms as assessed by the MADRS-S and 
comorbid depression were found to be significant predictors (i.e. more years with SAD, 
less depressive symptoms/ absence of depression predicted better outcome). General 
anxiety measured by the BAI was a significant moderator, showing that lower general 
anxiety was associated with absence of SAD diagnosis in ICBT but not in CBGT. Type 
of SAD (generalised or not) did not moderate outcome. The final model retained age 
and comorbid depression as predictors and general anxiety as a moderator. 
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3.5.3.2.3 Process related measures 
Higher treatment credibility and adhering to treatment predicted better outcome. 
Computer skills did not moderate treatment effects. Treatment adherence remained 
significant in the final model.  
 
3.5.3.2.4 Genetic factors 
As in the linear regression analysis, no genetic polymorphisms were significant 
predictors or moderators. Thus, no genetic data were included in the final multivariate 
model.  
 
Table 5. Logistic regression presenting the final model using SAD diagnosis  
(yes/no) at six-month follow-up as dependent variable.  
 
          
Variable          
 Chi-2  
 
 -2 Log 
Likelihood  
  
Cox & Snell 
R2  
  
Nagelkerke 
R2  P-value 
Model          
Omnibus Test 
(df=4)         <.001 
Chi-2, 34.63   134.61  .24  .33   
          
 B  
 
 SE  
  
Wald  
  
Exp (B)   
Predictors          
Age .50  .21  5.49  .20  <.01 
Comorbid 
depression 2.26  .82  7.58    <.02 
Treatment 
adherence (Yes) -1.61  .62  6.65  .20  <.01 
Moderator          
General Anxiety 
(BAI) -1.09  .40  7.56  .34  <.01 
          
Abbreviations: SAD, Social Anxiety Disorder; BAI, Beck Anxiety Inventory; Exp, exponentiated based  
on the natural logarithm 
 
3.5.3.3 Signal detection analysis of clinical improvement and decision tree  
The analysis yielded a model with three interacting predictors comprising treatment 
adherence, heredity of SAD, and depressive symptoms assessed by MADRS-S as best 
predictors (χ2=8.56-23.02, df=1, ps<.01). The subgroup with highest chance of 
achieving clinical improvement was that comprising participants adherent to treatment 
without heredity of SAS. The lowest chance of clinical improvement was found for 
those who a) did not adhered to therapy, or b) adhered to therapy but had heredity of 
SAD and were moderately to severely depressed. Figure 8 displays the clinical decision 
tree including optimal cutoff points. The odds ratio range was 3.84-16.00 indicating 
moderate effect of the predictors [259]. 
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Figure 8. Clinical decision tree based on signal detection analysis. 
 
Receiver operator characteristics (ROC) for predictor Treatment adherence: a) Sensitivity, 96.7%, b) 
Specificity, 38.6%; ROC for predictor Heredity of SAD, a) Sensitivity, 74.2%, b) Specificity, 57.1%; 
ROC for predictor Depressive symptoms, a) Sensitivity, 94.1%, b) Specificity, 50.0%. 
 
 
3.5.4 Discussion 
To my knowledge, this is the first trial aiming to identify demographic, clinical and 
genetic predictors and moderators of ICBT relative to traditional CBT for SAD. In both 
treatments having children, working full time, having less depressive symptoms, 
treatment adherence and higher expectancy of treatment effectiveness were significant 
predictors of six-month outcome. This was the case both when assessing outcome with 
the LSAS and when using SAD diagnosis as dependent variable. Contrary to our 
Heredity of SAD (Yes) 
n=37 
(45.9% clinically improved) 
More depressive symptoms 
 (MADRS-S≥20)  
n=11 
(9.1% clinically improved) 
Lowest chance of improvement 
Depressive symptoms 
Less depressive symptoms 
 (MADRS-S<20) 
n=26 
(61.5% clinically improved) 
Heredity of SAD (No) 
n=67 
(76.6% clinically improved) 
Highest chance of improvement 
Heredity of SAD 
Clinically improved 
n=69 
(54.8% of total sample) 
Treatment adherence 
Did not complete treatment 
n=25 
(12% clinically improved) 
Completed treatment 
n=101 
(65.3% clinically improved) 
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hypothesis, none of the investigated genetic polymorphisms predicted treatment 
outcome. The final linear regression model explained more than 50% of the variation of 
the main outcome measure LSAS at follow-up, suggesting that it might be highly 
valuable for the clinician to assess these factors when planning and evaluating 
treatment.   
 
The primary limitation of this study common to most RCTs is the inherent restriction in 
terms of predictors and moderators as those likely to have the strongest impact on 
outcome are part of the exclusion criteria. Nevertheless, this trial was an effectiveness 
trial which aimed to include patients normally seen in regular psychiatric settings. This 
means that there were relatively few restrictions, e.g. comorbid psychiatric diagnosises 
were allowed. An additional limitation is that power to detect predictors and 
moderators with small effect sizes was limited. However, predictors with very small 
effects are often of limited clinical relevance.  
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4 CONCLUDING DISCUSSION 
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4.1 PRIMARY FINDINGS 
This thesis provides new evidence clearly demonstrating that Internet-based cognitive 
behaviour therapy (ICBT) for social anxiety disorder (SAD) is an effective treatment in 
an experimental as well as in a clinical setting. The studies of this thesis have also 
shown that effect of ICBT is enduring over at least half a decade and that the treatment 
is cost-effective in comparison to conventional CBT. Also, new clinically useful 
knowledge regarding determinants of outcome is provided. In the following section, the 
results are discussed in greater detail. 
 
4.1.1 Efficacy of ICBT for SAD 
The findings of the present thesis indicate that ICBT is an efficacious treatment for 
SAD. Thus, one can claim with a high degree of certainty that ICBT leads to a large 
reduction of social anxiety as well as to improvements regarding depressive symptoms, 
general anxiety and quality of life. The randomised design of Study I makes it possible 
to draw the conclusion that the demonstrated improvements were caused by the 
treatment and would not have occurred in the absence of it. Taken together with the 
results from other RCTs investigating the efficacy of ICBT for SAD, conducted by 
independent research groups, the evidence supporting the treatment is massive [13, 14, 
208-211, 215-217, 260].  
 
However, the mechanisms of the treatment are less well understood. In Study I, the 
results only partially supported our hypothesis that ICBT would be superior to 
unguided bibliotherapy. As a matter of fact, as the bibliotherapy group made moderate 
to large improvements, neither the online features nor the therapist contact seem 
necessary to produce treatment gains. This suggests that the content of the treatment is 
important, i.e. the self-help texts which on which the treatment heavily relies.   
 
As bibliotherapy performed relative well on measures of social anxiety, it is warranted 
to ask whether the online features, which require therapist time to operate and 
substantial  costs to develop, are redundant. The answer to that question depends on 
perspective. First, the scientific evidence supporting bibliotherapy for SAD is much 
more limited. Only four RCTs have been conducted using unassisted self-help and only 
those conducted by my research group have demonstrated strong effects [185, 186, 
210]. For example, on the measures SIAS and SPS, employed across studies, effect 
sizes ranged between 0.28 and 0.38 (albeit higher if analysing only completers) [185, 
210] in the other studies compared to a 0.65-67 effect size range in Study I [186].  
Second, although our prediction that ICBT would be superior to bibliotherapy was only 
partially supported, there was a trend towards stronger effect for ICBT. The average 
baseline to follow-up effect size on social anxiety measures was 1.40 in the ICBT 
group compared to 0.86 in the bibliotherapy group.   
 
Assuming effect sizes of the magnitude found in Study I were generally true, 
bibliotherapy would be a good option under the circumstance that one were willing to 
pay very little for additional gains compared to no treatment. This would be the case in 
countries or regions with no or very limited funds to provide other treatments for SAD. 
Nevertheless, the effect sizes are too small to be sufficient if one has the ambition to 
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provide a treatment that is as effective as conventional CBT. Further arguments in 
favour of ICBT rather than bibliotherapy, increasingly relevant to modern psychiatry, 
are the possibilities to easily and efficiently evaluate and monitor the treatment.   
  
4.1.2 Effectiveness of ICBT for SAD 
Effectiveness refers to the degree to which a treatment is feasible and can produce 
strong effects in real-world clinical situations [205, 206]. Study II of this thesis has 
demonstrated that ICBT can be at least as effective as cognitive behavioural group 
therapy (CBGT) when delivered in a psychiatric setting. Thus, ICBT does not only 
produce large effects when offered in a university context to self-referred patients using 
primarily self-assessments and telephone interviews, but also within regular health care. 
Important to bear in mind is that effectiveness not only refers to the characteristics of 
the patients. Indeed, Titov and co-workers found that although a sample from an 
outpatient clinic had more social anxiety according to the SPS (but not on the SIAS) 
and were more likely to be single compared to Internet clinic patients, on most 
variables the two patient groups were similar [261].  
 
This means that the effectiveness strengths of Study II lie mainly elsewhere. One of the 
most important is that the general rule was that patients were assessed and treated by 
psychiatrists and psychologists working as clinicians and not researchers. This is an 
important aspect as it means that ICBT proved to be effective and feasible even when 
delivered under regular care reinforcement contingencies. That is, the persons involved 
carried out their work as part of clinical routing practice, and thus were not unusually 
highly motivated by scientific reinforcers. Taken together with the open trial [214] and 
the recently published Australian RCT [207] conducted in a psychiatric outpatient 
setting, the conclusion is that ICBT for SAD is an effective treatment. Another strong 
indication of the treatment’s effectiveness is that all accumulated evidence contains no 
conflicting results. That is, the work by Titov and co-workers in Australia and by 
Berger and colleagues in Switzerland together with the studies by my research group, 
under the supervision of Andersson and Lindefors, all indicate that ICBT for SAD is 
effective. This is displayed in Table 6 below presenting main results from all published 
RCTs in the field. 
 
A limitation of study II in terms of effectiveness is that participants were randomised to 
the treatment arms. This is unrealistic to happen in clinical routine practice and the only 
way to get around this problem of external validity is to deliver the treatment outside 
the context of a research study and evaluate the treatment as part of regular care. 
Partially as a consequence of the findings presented in this thesis, the ICBT for SAD 
described herein is now available at the Internet Psychiatry Clinic in Stockholm, 
Sweden (www.internetpsykiatri.se) within the context of regular psychiatric health 
care. More than 200 patients with SAD have received treatment and preliminary 
analyses indicate that the treatment yields large to moderate effect sizes. Considering 
the nature of ICBT, it is theoretically plausible that it would transfer well to a clinical 
setting. In conventional psychological treatment, therapist drift refers to the tendency of 
therapists to divert from the protocol when delivering treatment in clinical settings 
[262]. Because of the firm structure of ICBT, e.g. fixed modules and homework 
assignments, this is unlikely to occur. In conclusion, empirical evidence as well as 
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theoretical arguments suggest that ICBT for SAD is an effective treatment also when 
delivered in regular health care.  
 
Table 6. Overview of RCTs investigating the effect of ICBT for SAD 
 
Country 
[reference] 
Treatment 
arms N 
Out-
come 
meas-
ure Main results 
Effect size d of active 
treatment (Pre-Post) 
(note: arms as denoted in 
second column) Setting Year 
Sweden 
[13] 
a. ICBT + 
exposure  
b. WLC 
64 LSAS-
SR 
ICBT superior to WLC a. 0.91 University, 
Self-referral only 
2006 
Sweden  
[14] 
a. ICBT + 
tel. support 
b. WLC 
60 LSAS-
SR 
ICBT superior to WLC a.1.00 University,  
Self-referral only 
2007 
Sweden 
[209] 
a. ICBT + 
exposure  
b. ICBT 
38 LSAS-
SR 
Over-lapping CIs of 
TXs 
a. 0.82 
b. 1.01 
University, 
Self-referral only 
2008 
Sweden 
[Study I] 
a. ICBT 
b. BIB 
c. WLC 
120 LSAS-
SR 
ICBT and BIB superior 
to WLC, ICBT partially 
superior to BIB 
a. 0.93 
b. 0.78 
University, 
Self-referral only 
2009 
Sweden 
[186] 
a. ICBT 
b. BIB 
c. BIB + DG 
d. IAR 
115 LSAS-
SR 
Superiority not 
established 
a. 1.35 
b. 0.71 
c. 1.42 
d. 0.99 
University,  
Self-referral only 
2009 
Sweden 
[Study II] 
a. ICBT 
b. CBGT 
126 LSAS ICBT at least as 
effective as CBGT 
a. 1.42 
b.  0.97 
Outpatient clinic, 
referral and self- 
referral 
2011 
Australia  
[211] 
a. ICBT 
b. WLC 
105 SIAS, 
SPS 
ICBT superior to WLC a. 1.24 (SIAS) 
a. 1.06 (SPS) 
University, 
Self-referral only 
2008 
Australia 
[212] 
a. ICBT 
b. WLC 
88 SIAS, 
SPS 
ICBT superior to WLC a. 1.21 (SIAS) 
a. 1.14 (SPS) 
University,  
Self-referral only 
2008 
Australia  
[210] 
a. ICBT 
b. Unguided 
ICBT  
c. WLC 
98 SIAS, 
SPS 
ICBT superior to 
Unguided ICBT and 
WLC, Unguided ICBT 
not superior to WLC 
a.1.47 (SIAS) and 1.17 
(SPS);  
b. 0.36 (SIAS) and 0.28 
(SPS) 
University, 
Self-referral only 
2008 
Australia 
[213] 
a. Unguided 
ICBT 
b. Unguided 
ICBT + tel. 
reminders 
168 SIAS, 
SPS 
Unguided ICBT + tel. 
reminders superior to 
unguided ICBT 
a. 1.41 (SIAS) and 0.89 
(SPS);  
b. 0.98 (SIAS) and 0. 73 
(SPS) 
University,  
Self-referral only 
2009 
Australia  
[208] 
a. ICBT + 
technician 
aid 
b. ICBT with 
guided DG 
85 SIAS, 
SPS 
ICBT+ technician aid 
equivalent to ICBT + 
guided DG 
a. 1.47 (SIAS) and 1.15 
(SPS)  
b. 1.56 (SIAS) and 1.15 
(SPS) 
University, 
Self-referral only 
2009 
Australia  
[215] 
a. ICBT 
b. ICBT + 
motivational 
support 
113 SIAS, 
SPS 
ICBT + enhancement 
not superior to ICBT 
a. 1.16 (SIAS) and 1.04 
(SPS); b. 1.15 (SIAS) and 
0.75  (SPS) 
University,  
Self-referral only 
2010 
Australia 
[207] 
a. ICBT 
b. Group 
CBT 
37 SIAS, 
SPS 
Superiority not 
established 
a. 0.74 (SIAS) and 0.58 
(SPS)  
b. 0.89 (SIAS) and 0.82 
(SPS)* 
Outpatient 
Anxiety 
Disorders Clinic, 
GP referral 
2011 
Switzerland 
[216] 
a. ICBT 
b. WLC 
52 LSAS-
SR 
ICBT superior to WLC a. 0.82 University,  
Self-referral 
2009 
Switzerland 
[217] 
a. ICBT 
b. U-ICBT 
c. Flexible 
supported  
ICBT 
81 LSAS-
SR 
Superiority not 
established 
a. 1.53 
b. 1.48 
c. 1.41 
University,  
Self-referral 
2011 
        
*=Calculated by thesis author (not in paper); Abbreviations: ICBT, Internet-based Cognitive Behaviour Therapy; 
BIB, Bibliotherapy; WLC, Waiting list control; TX, Treatment; U-ICBT, Unguided ICBT; DG, Discussion group; 
Tel., telephone; LSAS-SR, Liebowitz Social Anxiety Scale-self report; SIAS, Social Interaction Scale; SPS, Social 
Phobia Scale. Note: study by Botella et al. [260] not included in the table as it was restricted to fear of public 
speaking.    
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4.1.3 Long-term effect of ICBT for SAD 
An important aspect of ICBT for SAD is whether the effects are enduring. As the 
results from Study III showed, the course of improvement seems to be that participants 
are moderately improved immediately after therapy and make further improvements 
within the following year. These effects are in turn enduring over at least five years. 
These results extend the previous research on ICBT for SAD using a shorter follow-up 
period [238]. Interestingly, the effects demonstrated in Study III are in line with those 
of the only five-year follow-up trial of conventional CBT for SAD I have found [235].  
 
It is quite remarkable that a treatment over nine weeks can yield such long-lasting 
effects, and of course a natural objection to the claim of long-term effectiveness is the 
uncertainty regarding cause and effect. For ethical reasons, it is highly doubtful to use 
waiting list or placebo controls that do not receive the active treatment for this long 
period of time. However, a study that came close to using a placebo group at five-year 
follow-up was the one by Heimberg and co-workers in which CBGT was compared to 
supportive group psychotherapy [235]. Although attrition rates were substantial, CBGT 
participants remained more improved than group psychotherapy participants at five-
year follow-up.  
 
As for Study III, what can be done is to make a theoretical estimate of the mechanisms 
of CBT and of what might have happened to participants in the control group had they 
received no treatment. In a study by Yonkers and co-workers, it was found that over a 
five-year period, the cumulative probability of achieving a full remission from SAD 
was 29% in men and 32% in women [69]. In comparison, 64% (51) of the participants 
in Study III were classified as very much or much improved at five-year follow-up, 
suggesting an additional effect of the treatment in relation to the natural course of SAD. 
Furthermore, as one of the most important proposed mechanisms of CBT for SAD is 
reduced anxiety by repeated exposure, it is theoretically predicted that gains are 
maintained as CBT stresses the importance of making long-term behaviour change 
[22]. As evidence in this field shows that results from efficacy studies can be 
generalised to clinical settings, it is fair to conclude that ICBT for SAD can be effective 
over half a decade.  
 
4.1.4 Cost-effectiveness and cost-utility of ICBT for SAD 
Study IV demonstrated that ICBT for SAD can be cost-effective compared to CBGT 
when taking a societal perspective. Intriguingly, the most likely outcome according to 
the economic evaluation was that ICBT yields incremental effects to a lower cost, thus 
being cost-effective compared to CBGT regardless of willingness to pay. As this is the 
only trial so far using a randomised control over potential confounders, it is a bit too 
early to claim strong evidence for cost-effectiveness of ICBT for SAD. However, 
results from a trial by Titov and co-workers using a different design is in line with the 
findings of Study IV [204].  
 
As would be expected from the concept of SAD from a CBT perspective, the reduced 
costs following treatment was in the realm of indirect non-medical costs i.e. loss of 
productivity. This suggests that the same components of treatment leading to reduced 
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social anxiety also cause patients to engage more in work related activities. The cost 
analysis showed that although the interventions introduced some costs of their own, 
these costs were offset by increased productivity levels within one year.  
 
Were the results of Study IV to hold, the decision to choose between ICBT and CBGT 
for SAD is relatively straightforward from a health care perspective. From a societal 
perspective, however, the preference of one treatment over the other is not as obvious. 
Assuming that both treatments yield about the same effects and are long-term effective, 
the relative cost-effectiveness of ICBT would likely diminish over time. This is because 
both treatments displayed the same effects in terms of cost reductions and the net cost 
benefit of ICBT was due to lower costs of treatment. Thus, with time the cost 
difference between treatments will be negligible compared to the societal economic 
gains that both treatments produce. In conclusion, in the shorter term ICBT is cost-
effective compared to CBGT from a health care and societal perspective. In the longer 
run, society might make fairly equal economic gains by increasing availability to either 
of the treatments. 
 
4.1.5 Determinants of treatment outcome of ICBT and cognitive 
behavioural group therapy for SAD   
The results from study V showed that patient demographics (having children, working 
full time), clinical characteristics (less depressive symptoms) as well as therapy process 
related measures (treatment adherence, higher expectation of treatment effectiveness) 
predicted better outcome of ICBT and CBGT for SAD. These factors were stable 
across different methods of measuring outcome. Overall, the hypothesis that stronger 
social support would be associated with better outcome was corroborated, potentially 
mediated through better opportunities to find suitable exposure situations. None of the 
investigated candidate genes had a significant predictive or moderating effect.  
 
As for moderators, general anxiety, and to a lesser extent, comorbid depression and 
personality traits of impulsivity were found to interact with treatment type on outcome. 
The picture that emerges is that ICBT tend to have incremental effects for persons with 
lower levels of general anxiety and depressive symptoms while CBGT could be more 
suitable for persons with “need for change and action” [252] and who are less inclined 
to plan activities thoroughly.  
 
These findings seem reasonable in that the full benefits of ICBT, e.g. the freedom to 
plan one’s own treatment and the possibility of going through treatment stages in an 
individualised pace, are probably best reaped if the overall level of psychiatric 
symptoms is somewhat lower. Furthermore, it makes sense that the advantages of 
CBGT, e.g. firm structure, clear cues for treatment actions including built-in exposure 
possibilities, are best capitalised upon if one is more spontaneous and non-planning.  
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Computer skills did not moderate treatment effects. Taken together with the finding 
that higher age predicted absence of SAD diagnosis, this refutes the notion that ICBT is 
for younger people with special interest in computers. 
 
These results have several theoretical and clinical implications. From a theoretical 
view, the predictors found in this study might be used as an empirical ground from 
which hypotheses of treatment interventions can be generated and tested. One could 
design experiments to test whether the total proportion of participants responding to 
treatment would increase if classifying participants a priori and randomising them to 
standard ICBT or augmented treatment. For example, younger patients with higher 
levels of depressive symptoms might benefit from a treatment with added social 
support. Regarding the null findings of genetic factors, the results suggest that the 
effects of these variables are fairly small and potentially complex.  
 
As stated above, the results of Study V has important clinical implications. These will 
be discussed below under the Clinical implications section taking all studies in the 
thesis into consideration. But first a few words on the most central methodological 
limitations of this thesis. 
 
4.2 METHODOLOGICAL LIMITATIONS 
I view the following limitations of the studies in this thesis as most essential. In none of 
the RCTs described here a credible placebo condition was used. This means that the 
specific mechanisms of the treatment remain unknown. As for Study II and III 
comparing two active treatments, the same limitation makes it possible to claim that the 
improvements would have occurred in the absence of treatment. Considering the 
chronicity of SAD [263], this is however very unlikely (participants in study II, IV an 
V had had suffered from SAD for 21 years on average). Second, all studies used 
inclusion criteria which might have imposed restriction of the samples compared to 
clinical settings, e.g. in terms of risk of suicidal behaviours. However, the aim was to 
use inclusion criteria that would resemble the ones used in clinical practice which 
meant allowing for psychiatric comorbidity. 
  
4.3 CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
The findings of this thesis are of clear clinical value. The main implication is that ICBT 
for SAD is ready for implementation and dissemination within a regular health care 
context. It is safe to say that the scientific evidence supporting the effectiveness and the 
safety of the treatment is substantial and of high quality. The Swedish Council on 
Health Technology assessment (SBU), the governmental agency that evaluates health 
care interventions, assesses the empirical support of treatments on a 4-point scale. 
According to this scale, a treatment can be considered having highest possible 
empirical support if its effect has been demonstrated in at least two high quality RCTs 
conducted by independent research groups without conflicting evidence [264]. These 
criteria are by far fulfilled when it comes to ICBT for SAD.  
 
When adding the findings regarding long-term effects and cost-effectiveness of ICBT, 
the advantages of this treatment are striking. As stated in the introduction section, CBT 
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is available to only a few for several reasons, not at least due to a lack of trained 
therapists. ICBT is probably the most promising way of increasing accessibility to CBT 
on a large scale. Not only can it be used as general mean of increasing the number of 
patients treated by each psychologist, it can in fact be the only realistic way of 
increasing accessibility in remote rural areas.  
  
Although effect sizes of ICBT for SAD may be in parity with those of conventional 
CBT, it is important to remember that about a third of patients receiving ICBT in 
Studies I-II were not clinically significant improved. One of the most central roles that 
ICBT can play in future psychiatric care is to constitute the first step of treatment, 
thereby setting free resources to provide treatment of more intensified and complex 
nature for those who do not respond to ICBT. This could be a new way of using 
resources more efficiently and thus increasing the overall proportion of patients that 
achieves remission from SAD. This would be a pivotal shift from psychiatry of today 
which so often is referred to as binary – either you get it all (i.e. the full conventional 
CBT) or nothing. In essence, ICBT ought to be a complement to conventional CBT, not 
a substitute.  
 
An important question is whether all patients should be offered ICBT. As demonstrated 
in Study V, treatment outcome varies depending on several demographic and clinical 
variables. In addition, some symptom profiles moderate the effect of ICBT and 
conventional CBT for SAD. This suggests that on a fairly early treatment stage, 
patients at high risk of non-responding could be identified. Instead of letting everyone 
go through ICBT in the standard fashion knowing that a substantial proportion will be 
treatment failures, an interesting alternative would be to differentiate treatment 
interventions based on these predictor variables.  
 
This does not mean that young, single patients with high levels of depressive symptoms 
and general anxiety automatically should be discouraged to be treated with ICBT. 
However, it might be of especially high clinical value to monitor these patients with 
additional carefulness and to have an alternative treatment plan ready to be 
implemented at an early stage. This could be face-to-face sessions with the same 
therapist as one is treated by online, pharmacological treatment with SSRIs, or perhaps 
in a near future, the combination of the extinction enhancing drug D-cycloserine and in-
session exposure.  
 
So, how does one actually implement ICBT for SAD within regular psychiatric care? 
As mentioned, the Internet Psychiatry Clinic in Stockholm operates as a regular unit 
within psychiatric health care. Today, persons with SAD are eligible to seek treatment 
although the clinic initially offered treatment for panic disorder and depression only. 
Several lessons are learned from this experience.  
 
First, as ICBT requires specific skills in terms of CBT competence, computer 
programming and diagnostic procedures, it should constitute a separate unit of 
psychologists and psychiatrists rather than being implemented as a treatment package 
in a general practitioner’s context. Although research has shown that many parts of the 
regular treatment procedure itself can be handled by less skilled personnel [208], it is of 
utmost importance that experienced and CBT trained psychologists are responsible for 
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the treatment. This is because complex cases need skilled supervision and that, in order 
to refine and develop the treatment, one has to have a profound understanding of its 
mechanisms, theoretically as well as practically.  
 
One other important aspect is high quality of diagnostic procedures. Because of the 
firm structure of the treatment, the therapist’s possibilities to adjust the treatment 
content in case of discovering that the patient has been misclassified diagnostically are 
limited (e.g. if it turns out that the patient has panic disorder rather than SAD). Thus, 
compared to regular outpatient psychiatric care, it is even more important that 
personnel conducting diagnostic assessments are highly competent in this regard.  
 
Finally, in order to truly serve the purpose of increasing availability to CBT, an 
important lessoned learned is to allow self-referral and not restrict ICBT to those 
referred from other health care providers. If adhering to these principles, it is my 
conviction that in the near future ICBT will be an indispensible part of regular 
psychiatric health care in the treatment of SAD. 
 
4.4 CONCLUSIONS 
This thesis has demonstrated that ICBT for SAD is efficacious, effective in a clinical 
setting, and cost-effective. Furthermore, the studies presented here have shown that it is 
possible to predict outcome of ICBT, and that ICBT yields improvements that are long-
term enduring. As I see it, this treatment is the most promising mean for making CBT 
available for the many persons affected by SAD who presently lack access to it. ICBT 
for SAD is ready for implementation and dissemination.        
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